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1.1 Genual introduction of telomerase in human tumours 
1.1.1 Telomerase and telomere 
1.1.1.1 The functions oftelomeres 
The chromosome ends are specialized nUcleoprotein stmctures called telomeres 
which "cap" the tennini of linear eukaryotic chromosomes and stabilize them, In 
humans, telomeres are made up of an averagc of 5000~15,OOO basc pairs of 
{TTAGGG}" repeats and telomere-binding proteins. Tclomeres foml specific 
complexes with telomere~binding proteins. They arc involved in chromosome 
replication, nuclear architecture, chromosomc stability, gene expression, human 
tumour fom13tiol1, aging and cell division (Greider, 1996; Blackburn, 1997). Owing to 
an inherent flaw in the way cells copy their DNA, each time a cell divides it loses 50~ 
100 base pairs at the cnd of its telomcrcs. This is known as the end-replication problem 
(Figure 1), as first described by Watson (Watson, 1972). 
The end replication problem predicts the progressive loss of chromosomal 
DNA at the 3' ends over multiple cycles of replication. When a telomere loses a critical 
number of basc pairs, it triggers a signal for thc ccll to stop dividing and senesce 
(Harley ct ai, 1990). Thus, telomere reduction is thought to be a biologic clock 
regulating the life span of a cell. Many unicellular organisms and vimses have evolved 
a special mechanism to circumvent the problem of tennilli. In these organisms, the 
chromosomes are circular, or the genome produces circular replicative intenllediates 
that simply lack ends so that the problem encountered in linear chromosomes does not 
exist (Hayflick, 1997). But the most common solution in higher eukaryotes is an 
enzyme complex called telomerasc, a specialised reverse transcriptase that synthesises 
telomeric DNA sequences and thus restores telomere length (Morin, 1989; Nakamura 
et ai, 1997). This process maintains a dynamic equilibrium and prevents the 
chromosomes from shortening to a critical length and prevents cells from receiving the 
signal to stop dividing. 
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Figure 1. End replication problem. Original chrolllosome strands are depicted in black thick lines. As 
the replication fork proceeds from left to right, the leading strands (rightward arrow) proceeds 
continuously to replicate one strand of original DNA. The direction of the lagging strand is opposite to 
the direction of the replication fork and relies on the ligation of Okazaki flagments (leftward arrows), 
which are primed with short stretches of RNA (empty boxes). Most RNA primers are replaced with 
DNA from an upstream Okazaki fragment, but the temlinal RNA primer (solid box) is never replaced 
with DNA. Consequently, each round of replication produces daugher chromosomes, which lack the 
sequences corresponding to tlle original 3' ends (bracket).The terminal primer actually may not anneal 
to the extreme 3' end, contributing to further loss of end sequences. (Figure cited from Rhyu, 1995). 
1.1.1.2 The telomerase-telomere complex 
In human, telomerase comprises of several protein subunits and an RNA 
component. The RNA component (human tclomerasc RNA, hTR), contains a domain 
that is complementary to one hexameric unit of thc DNA tclomcric repeat sequence, 
TTAGGG (Feng et ai, 1995). The protein moiety contains thc catalytic subunit (human 
telomerase reverse transcriptase, hTERT) that is homologous to reverse transcriptases 
(Nakamura et ai, 1997). Another moiety of protein (human te!omerase associated 
protein, TPl), was the first identified protein component, but the function as yet 
remains unknown (Harrington et ai, 1997). TIlliS, the enzymc complex comprises both 
template and polymerase activity. A simplified model of the telomerase-telomere 
reaction is shown in Figure 2. 
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Figure 2. Mechanism of telomere addition. Step I: 3' end of chromosomal DNA binds to the part of 
template region in telomerase RNA. Step 2: Telomerasc RNA provides the template for elongating the 
3' end of the chromosome (newly synthesized sequence in black and italics). Step 3: The chromosome 
is translocated and repositioned to repeat the polyrneri7.<ltion step. 
1.1.1.3 Human telomerasc, senescence and immortality 
Olovnikov was the first to suggest that gradual loss of chromosome ends could 
lead to an exit from the cell cycling compartment (Olovnikov, 1973). Subsequently, 
Harley and coworkers (Harley et aI, 1990; 1992) documented the relation between 
replicative senescence, immortalization and the shortening of teiomeres. In human 
cells, cellular senescence can be divided into two parts: Mortality stage I (MI) and 
Mortality stage 2 (M2). Immortalization of cells is associated with activation of 
telomerase at or near crisis in the M2 stage, as shown in Figure 3. In view of the 
substantial variation oftenninal restriction fragments (TRF) within a celJ pOJlulation, it 
has been proposed that senescence occurs when one or more TRF reaches a critical 
length (Allsopp and Harley, 1995). Inactivation of p53 and RB genes allows cells to 
continue to proliferate, despite critically short TRFs (Hara et ai, 1991; Wazer et ai, 
1995). But it is not known how these tumour suppressor proteins act in this capacity. 
They are proposed to prevcnt cells from sensing, or allow cells to bypass, the signal(s) 
generated by a critically short telomere. Also little is known as to how critically short 
telomeres result in cellular senescence. Possibly, cells respond to a short telomere as 
they do to DNA damage (Goldstein, 1990; Harley and Villcponteau, 1995). 
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Alternatively, a critically short telomere may sequester transcription factors that can 
activate or reactivate a variety of genes (Marcand et ai, 1996). 
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Figure 3, Model for telomere role ill senescence and immortality. (A) In somatic cells, telomerase 
activity is turned off by unknown mechanism(s). During cell divisions, te!omeres continue to shorten. 
(B) Telomere shortening reaches a critical point. (C) Some cellular factor(s) detect critically short 
telomeres, resulting in Ml crisis or exit from cell cycle and cells senesce. (D) Mutations in genes 
detecting genetic damage or regulating the cell cycle allow a clonal cell population to continue to 
divide and escape senescence, resulting in further telomere loss and chromosomal instability. (E) 
Further cell dh'ision leads to r.,·12 crisis and most cells die. (F) Rare cells require teiomerase activity and 
their telomeres are stabilized. These cells are immortal. (Figure cited from Rhyu, 1995) 
1.1.1.4 TRAP assay 
A critical step in the evolution oftelomerase studies has bccn the developmcnt 
ofa specific and sensitive method for the detection oftelomcrase activity. The general 
used Telomeric Repeat Amplification Protocol (TRAP) is a very sensitive assay (Kim 
et ai, 1994). It can detect telolllcrase activity in as few as 1-10 positive cells and 0.0 I % 
positive cells in a mixed population, thereby allowing the lise of very small amounts of 
tissue (Wright et ai, 1995). However, as pointed out by Meeker and Coffey (Meeker 
and Coffey, 1997), thcrc arc many pitfalls in assaying telomerase activity, including 
inadequate handing of samples, sampling artefacts, contamination with tclomcrase 
positive material and peR inhibitors, Imperfectly prescrved tissue samples and Taq 
polymerase inhibitors are considered as the two main reasons for false-negative 
results in teiomerase activity assays. An intemal control is included in the 
6 
conventional TRAP assay, to test for Taq polymerase inhibitors, whereas little 
attention has been paid to potential false-negative results due to inadequately 
preserved tissue samples. As telomerase, a ribonucleoprotein enzyme, uses its RNA as 
a template and its catalytic subunit as reverse transcnptase for the synthesis of the 
TT AGGG repeats, it stands to reason that the assay functions only when the protein is 
active and the RNA is non-degraded. These two conditions indicate that the quality of 
the tissue is of vital importance for the reliability of the telomerase activity assay. 
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Figure 3. TRAP assay for tclomerase acthity. Step I. An extract is prepared from fresh tissues or 
cells by detergent lysis buffer. Step 2. Addition oftelomeric rcpeats by te1omerase. Telomerase adds a 
number ofte1omeric repeats (GGITAG) on to the 3' end of a substrate oligonuleotide (TS) using added 
deoxynucleolide triphosphates (dNTPs). Since telomerase is a processive enzyme, the products of this 
reaction will be heterogeneous in length. Step 3. Amplification of TS-Ielomerase product by PCR. The 
extended products are amplified by PCR using the TS and RP (reverse) primers, generating a ladder of 
products with 6 base increments. Step 4. llte amplified products are run 011 a polyacrylamide gel. 
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1.1.2 Telomerase components 
As mentioned above, telomerase consists of at least three components: hTR, 
hTERT and TPI. Their functions and the regulatory mechanisms by which tclomerase 
is activated have not been fully deteonined. The detection of individual telomerase 
components requires methods to assay hTR RNA, hTERT mRNA and hTERT protein. 
Molecular biological and histochemical methods for their detection have meanwhile 
been developed. 
1.1.2.1 Telomerase associated protein (TPl) 
The presence of TPI, of which the function as yet remains unknown, is not 
correlated with telomerase activation. It is ubiquitously expressed (Ramakrisllllan et 
aI, 1998; Takakura et aI, 1998). Thus, TPI apparently does not playa cnlcial role in 
telomerase activation. It could be required ill vim for full tclomcrase asscmbly, 
function and functional regulation, but its presence can not be used as an indicator of 
telomerase activation. 
1.1.2.2 Telomerase RNA 
hTR, the fust component identified, acts as a template for telomere elongation 
by telomerase. In reconstituting human telomerase activity, hTR is an essential 
component (Weinrich et aI, 1997; Beattie et ai, 1998). Tumour cells transfected with 
antisense hTR lose telomeric DNA, resulting in cellular senescence (Feng et ai, 1995). 
These findings suggest that hTR is indispensable for telomerasc activity. It is 
conceivable that telomerase activity correlates with hTR expression. However, 
controversial results have been reported regarding this issue. A correlation has been 
found between telomerase activity and hTR expression, as detennined by in situ 
hybridization; but the level of telomerase activity did not parallel the level of hTR 
expression (Soder et ai, 1998; Heine et ai, 1998; Paradis et ai, 1999; Maitra et ai, 
1999). Recent studies demonstrated that hTR RNA, detected by RT-PCR, is widely 
expressed in both cancerous and non-cancerous tissucs, although in cancer tissue at a 
higher level (Ramakrishnan et ai, 1998; Takakura et ai, 1998; Kyo et ai, 1999; Sumida 
et ai, 1999). The fact that the hTR gene has no introns requires specific consideration. 
hTR eDNA is identical to genomic hTR DNA and, as it is very difficult to avoid the 
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presence of traces of genomic DNA in extracted RNA, Juring PCR amplification genomic 
hTR DNA might be co-amplified, leading to false-positive results. 111is might explain 
why, by RT-PCR, hTR RNA has been found in cancer and lion-cancer tissues, 
irrespective of telomerase activity. This problem can be circumvented by extensive 
DNase digestion of the extracted RNA before cDNA synthesis. Very few RT-PCR 
experiments were perfonned with the use of DNase before cDNA synthesis (MUller et 
ai, 1998; Yasui et ai, 1998; Dome et ai, 1999; Stanta et ai, 1999). In a recent report, 
nomlal urine samples were analysed and hTR was detected in only 15% of them 
whereas 83% of the urine samples from the patients with bladder cancer were found 
hTR-positive (MiilIer et ai, 1998). In gastric tissues, Yasui et al have observed that 
telomerase activity was associated with increased hTERT and hTR expression (Yasui 
et ai, 1998). Unfortunately, in Ihe other two papers, no nOnllal tissues were analysed 
(Dome et aI, 1999; Sianta ct al. 1999). 
1.1.2.3 The reverse tmnscriptase subunit 
hTERT has been identified as the putative human telomerase catalytic subunit 
(Nakamura et aI, 1995). The expression of hTERT is closely correlated with 
telomerase activity ill vitro and ill vivo (Nakamura et aI, 1995; Meyerson et ai, 1997). 
Transfection of plasmids encoding hTERT resulted in telomerase activity, telomere 
maintenance, and extension of life span in foreskin fibroblasts and retinal epithelial 
cells (Bodnar et ai, 1998; Morales et ai, 1999). More recently, Hahn and coworkers 
reported that the ectopic expression ofhTERT in combination with two oncogenes (the 
simian virus 40 large-T oncoprotein and an oncogcnic allele ofH-ras) resulted in direct 
tumorigenic conversion of nonnal human epithelial cells and fibroblasts (Hahn et aI, 
1999). Regulation of the hTERT expression has been proposed as the major 
detemlillant of the regulation of the cnzymatic activity. hTERT mRNA, determined by 
either RNase protection or RT-PCR analysis, appears to bc expressed at high levels in 
primary tumors, cancer cell Jines, and telomerase-positive tissues but absent in 
telomerase-negativc cell lines and in differentiated tissues (Nakamura et aI, 1995; 
Meyerson et ai, 1997). hTERT mRNA has also been found in some telolllerase~ 
negative normal tissues in olher studies (Ramukrishnan ct ai, 1998; Tahara et aI, 1999). 
By in situ hybridization, hTERT was present not only in carcinoma tissues but also in 
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nannal epidennis, even at high levels in the basal layer of the epidennis (Kalquist et 
aI, 1998 Nakano et ai, 1998). By immullohistochemistry, hTERT protein was found in 
all crypt epithelial cells of BannaI colon mucosa except those at the top, although at a 
lower level than in cancer cells, In crypts more cells were hTERT positive than Ki-67 
positive (Takara et aI, 1999), 
1.1.3 Human tclolllcrasc and cancer 
The telomere-telomerase hypothesis of cell aging has rapidly become a focus 
of intensive research in the field of carcinogenesis. The hypothesis is based on the 
observation that telomerase activity is expressed in embryonic cells, in adult genllline 
cells (Kim ct ai, 1994; Wright ct ai, 1996), and in most human tumours (Kim et ai, 
1994; Avilion et ai, 1996; Shay et ai, 1997), but is undetectable in nonnal somatic 
tissues except for proliferative cells of renewable tissues including haemopoietic stem 
cells (Hiyama K et al,1995; Broccoli et aI, 1995; Chin et aI, 1996), activated 
lymphocytes (Hiyama K et ai, 1995 ), basal cells of the epidenllis (Taylor et ai, 1996; 
Harle-Bachar ct ai, 1996) and intestinal crypt cells (Hiyama E et aI, 1996), Meeker 
summarised Illore than 2600 human tumour samples that have been tested for 
tclomerase activity using TRAP assay. The overall prevalence of 84,9% makes 
telomerase activity the most common biochemical marker of human cancer (Meeker et 
aI, 1997). However, telomerase activity as a diagnostic parameter is confounded by 
the presence of the enzyme in certain benign lesions or in BannaI tissues. For example, 
telomerase is activated in up to 95% of breast cancers, absent in nomml breast (Carey 
et aI, 1998), detectable in 60% of benign fibroadenomas (Poremba et ai, 1998). In 
lymphoma (Yashima et aI, 1997), skin cancer (Taylor et at, 1996) and ovarian cancer 
tissue samples (Murakami et ai, 1997), significant numbers ofnonnal cells were found 
with telomerase activity. Quantitation oftelomerase activity might help to resolve this 
issue, 
1.1.3.1 Telomerase activity in colorectal carcinogenesis 
Telomerase is activated in some premalignant lesions, such as hyperplasia and 
dysplasia in the lung (Breslow et ai, 1997), dysplasia and carcinoma in situ in the 
oropharynx lesions (Califano et ai, 1996), as weIl as in premalignant skin lesions 
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(Parris et aI, 1999). However, at which moment in the multistep pathogenesis of cancer 
telomerase is activated remains to be clarified. If telomerase could be used to detect 
preinvasive neoplasia, tIus could then be treated with greater efficiency and lesser 
toxicity than for invasive cancer. 
Colorectal adenoma-carcinoma sequence is one of the most elaborated models 
for multiple step tumourigenesis. Tissue samples from different stages can be obtained 
relatively easily, which has allowed characterisation of the histopathological steps and 
the accompanying genetic alterations. Gradual progression from adenoma to 
carcinoma has also allowed to identify at which step telomerase is activated. 
Telomerase activity has been found in almost all colorectal carcinomas, irrespective of 
tumour stage and histological type. The reportcd incidence of telomerase activity in 
colorectaI adenomas varied from 0-100% (Chadeneau ct ai, 1995; Avillion et ai, 1996; 
Tahara et aI, 1995; Tang et ai, 1998). Telomcrase activity was detected in 50% of 
eolorectal precancerous lesions {hyperplastic polyps (15%), villous adenomas (50%) 
and tubular adenomas (45%)] by Tabara (Yahara et ai, 1995). Chadeneau and Avillion, 
however, reported absence of tclomerase activity in colorecta1 adenomas (Chadeneau 
et aI, 1995; Avillion et ai, 1996). Another group found telomerase activity in 16% of 
small «l.Ocm) polyps, 20% ofintemlediate polyps and 71% of large (>2cm) polyps 
(Tang et ai, 1998). Fang and coworks detected, in a series of colorectal tissues 
obtained by biopsy, telomerase acth'ity in 88.5% (46/52) of colorectal carcinomas, in 
50% (6/12) of colonic adenomas but not in nonnal coloreetal mucosa (Fang et ai, 
1999). No correlation was observed between telomerase activity and tumour location, 
type, size or differentiation. Tclomerase activity has not been studied in detail in 
Hornlal colon mucosa, but has been found in the bowel wall. It has been suggested that 
the enzyme activity Blight originate from stem cells in the lower third of the mucosal 
crypts or frolll lymphotytes in the submucosa (Hiyama E et ai, 1996; Breslow et ai, 
1997). Telolllerase activity occurs in adenomas but no data shows unambiguous 
correlation between teiomerase activity and grade of dysplasia in colorectal adenomas. 
1.1.3.2 Telollierase activity in noninvasive or minimally invasive samples 
Telomerase activity has been detected in almost any type of clinical specimen, 
including exfoliated cells and fine needle aspirates. For example, it has been detected 
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in oropharynx in the context of head and neck cancer (Califano et ai, 1996); in colonic 
washings in search of coloretal cancer (Yoshida et ai, 1997 A); cervical scrapings in 
search of cervical cancer (Kyo et ai, 1997) and in bladder washings or urinary samples 
for urinary tract cancer (Kavaler et aI, 1998; Yoshida et aI, 1997 B); and also in fine-
needle aspiration biopsies in search of breast, prostate, thyroid and liver cancers 
(poremba et ai, 1998; Lin et ai, 1998; Haugen et ai, 1997; Nakashio et aI, 1997). One 
of the limitations of the detemlination oftelomerase activity, notably in such samples, 
is the risk of false-negative or false-positive results. Telomcrase activity might not be 
found in a cancer samplcdue to incomplete sampling or due to suboptimal preservation 
of the sample. On the other hand, teiomerase activity can also be found in a sample 
without cancer cells when telomerase-positive stem cells or inflammatory cells are 
present. Nevertheless, the TRAP assay for telomerase activity Illay has potential as a 
screening tool. It is important to detennine whether tclomerase can he measured 
correctly in samples obtained from patients using non or minimally invasive 
procedures, The llse of telomcrase assay in minimally invasive procedures, such as 
cytological diagnosis for pleural or peritoneal effusions, may hold great promise for 
aiding clinical diagnosis prior to surgery and in some instances, in which the cytology 
is not infonnativc, may help differentiate benign from malignant effusions. 
1.1.3.3 Telomcrase activity in soft tissue sarcomas and the alternative 
mcchanisms for lengthening of tcloJllcrcs 
Schneider-Stock found that telomeric lengths vary in soft tissue sarcomas 
(Schneider-Stock et ai, 1998); telomerase was activated in only 69% of liposarcomas 
(Schneider-Stock et ai, 1999). No data was presented conceming telomerase activity in 
other types of soft tissue sarcomas. Clearly, sarcomas need to be studied more closely, 
The available data suggest, however, that immortalization of mesenchymal cells might 
imply different mechanism than immortalization in epithelial cells. Immortalization of 
human cells in culture is usually associated with telolllcmse activation, However, some 
human celJ lines immortalised ill vitro have been found to have no detectable 
telomerase activity, such as IIlCF-T/A6 (fibroblast derived) and BET-3M (bronchial 
epithelial cell derived) (Bryan et ai, 1995). Mixing experiments showed that inhibitors 
of telomerase or of the TRAP assay are not responsible for these negative results, The 
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extreme heterogeneity in telomere length, and the differences in the dynamics of 
telomere maintenance in te!omerase-negative cell lines compared to telomerase-
positive cell lines, indicate that these cells might have utilised one or more altemative 
mechanisms for lengthening of telollleres (ALT) (Bryan et ai, 1995; Henderson et ai, 
1996; Lansdorp et ai, 1997). ALT is not restricted to ceillincs immortalised ill vitro, 
but has also been found in 4 of 56 tumour-derived cell lines. 3 of these 4 ALT cell 
lines were derived from sarcomas (Reddel et ai, 1997). Bryan and co-workers 
discovered that immortalised cell lines derivcd ill vitro from fibroblasts were more 
frequently ALT-positive than immortalised cell lines derived ill w·lro from epithelial 
cells (Bryan et ai, 1997). More recently, Yeager el al. reported that ALT cells and 
tumors contain a novel promyelocytic leukemia (PML) body (ALT-associated PML 
body, APB) in which PML protein colocalized with telomeric DNA and the telomere 
binding protein hTRFl and hTRF2. APBs were foulld in ALT tumors and cell lines 
but not in mortal cell strains or in telomerase-positive cell lines or tumors (Yeager et 
ai, 1999). 
1.1.4 Perspectives 
The discovery oftelomerase has provided us a potentially powerful Ilew marker 
and prognostic indicator as well as a target for new cancer therapies. The field is 
moving rapidly and in a limited time framc, much has been discovered concerning the 
stmcture and function of telomerase, but it is a still relatively new area and much 
further work is needed to allswer following questions. 
(1) How is telomerase activity regulated? 
(2) Are there aitemative telomere lengthening mechanism? 
(3) Can a telomerase assay be used as a diagnostic and prognostic marker in neoplastic 
lesions? 
(4) Are telomerase blocking reagent potentially valuable ncw therapeutic approaches? 
1.1.4.1 Regulation of telomerase activity 
Cancer is essentially a disease invoving dynamic changes in the genome. The 
foundation for this concept has been set in the discovery of mutations that produce 
oncogenes with dominant gain of fuction and tumour suppressor genes with recessive 
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loss of function. The expression of telomerase activity is likely regulated by various 
oncogenes and tumour suppressor genes, both directly and indirectly. The mechanism 
of regulation of telomerase is currently focused on hTERT gene. Sequence analysis 
has revealed that the hTERT promoter contains binding sites for several transcription 
factors suggesting that hTERT gene expression might be regulated by different factors 
(COllg et ai, 1999; Wick et ai, 1999). Recent studies shown that the proto-oncogene c-
Myc activates telomerase by inducing expression of its catalytic subunit (Wang et ai, 
1988; \VU et aI, 1999). Introduction of chromosome 3 into telomerase-positive cell 
lines, human renal carcinoma (Horikawa et ai, 1998; Tanaka et ai, 1998) and breast 
cancer cells (Cuthbert et ai, 1999) induces repression ofhTERT expression. A putative 
telomerase repressor gene has been further mapped to chromosome region 3pI4.3-
p21.3 (Tanaka et ai, 1998; Parkinson et ai, 1997). In addition, up-regulation of 
telomerase is associated with introduction of HPV -16 E6 protein (Klingelhutz et aI, 
1996; Kiyono et ai, 1998), SV40, v-K-ras (Burger et aI, 1998; Rhim et ai, 1998) and 
BcI-2 (Mandai et ai, 1997) and downregulation with introduction or overexpression of 
retinoblastoma protein (Xu et ai, 1997; Nguyen et ai, 1999). Taken together, activation 
oftelomerase might be regulated by Illany factors at multiple level. 
More recently DNA methylation has been found to playa role in gene silencing 
(Hennan et al,1994) and as a mechanism for the loss of function of tumour suppressor 
gene in the onset or the progression of cancer (Sakai ct ai, 1991; Henllan, 1999; Baylin 
et ai, 1998). Hypomethylation of DNA is associated with increascd gene expression 
(Ferguson et ai, 1995), and might be involved in activation of oncogenes. Gene 
transcription can be activated by treatment with demethylating agents (Venolia et aI, 
t 983). Therefore, DNA methylation of cytosine in CpO sites of promoter regions is 
considered the most common mechanism for repressing of genc expression. Even a 
unique methylated CpO site in the promoter region is sufficient for a significant down 
regulation of ill vivo transcription. Based on these consideration, we propose that DNA 
methylation might playa role in the regulation of telomerase activity. Future In depth 
is needed to analyse to what extent DNA methylation in the promoter regions of hTR 
and hTERT genes, plays a role in the (de)activation ortelomerase. 
1.1.4.2 Alternative mechallism(s) for maintaining telomere length 
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Immortalization of human cells in culture is usually associated with telomerase 
activity. In some cases, however, telomerase appears not to be activated. Heterogeneity 
of telomere length has been found between chromosomes in individual telomerase-
negative cells (Henderson et ai, 1996; Landsdorp et ai, 1997) and between telomerase-
negative human tumours (Schneider-Stock et ai, 1998; 1999). Long telomeres suggest 
that telomere lengthening has occurred. Extreme heterogeneity in telomere length in 
teiomerasc-negative cells suggest that they Illllst have utilised one or more altemative 
mechanisms of telomere elogation (ALT). The nature of the ALT mechanism(s) in 
human is currently unknown, eukayotes use two other mechanisms for maintenance of 
telomere length: recombination (Wang and Zakian, 1990) and relrotransposition 
(Moore and Haber, 1996; Teng et ai, 1996). A detailed understanding of AL T will be 
necessary in order to increase efl:1ciency of cancer therapy by telomerase inhibitors. 
Much further study is needed, even though ALT appears to be present in only a 
minority of tumours. The ALT-associatcd P~\'tL body (APB) provides a simple marker 
for ALT. Soft tissue sarcomas constitute an interesting model to study the ALl' 
mechanisOl{s) in human tissues. 
1.1.4.3 Telomerase in diagnosis and prognosis of neoplasia 
Many publications agree that telomerase activation can be used as a criterion 
to diagnose neoplasia of the colon, head and ncck, lung, and skin, even at 
a preinvasive stage. Future studies arc needed to detennine the value of te!omerase 
activity and the expression of its components (hTR and hTERT) for (early) cancer 
diagnosis. 
Other studies revealed that telomerase activity is associated with clinical 
outcome ill certain cancers. Telomerase activation has been shown to correlate with 
poor clinical outcome in gastric cancer (Tahara E et ai, 1996), breast cancer (Kim et ai, 
1994), ordinary minigioma (Longford et ai, 1997) and neuroblastoma (Hiyama et ai, 
1995). Telomerase activity has been also found to correlate with pathological stage 
(Tahara et ai, 1995) or tumour aggressiveness (Ohyashiki et aI, 1997; Hoos et ai, 
1998). Futhennore, the level of telomerase correlates with survival rates of patients 
(Hiyama E et ai, 1995; Langford ct ai, 1997). Future studies should focus on 
distinguishing the pre-cancerous lesions that will likely progress to invasive cancers 
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from the ones that will not, predicting the clinical course of a patient after the cancer 
has been diagnosed, and monitoring the effectiveness of cancer therapy. For some 
types of cancer, telomerase might be one sllch marker. 
1.1.4.4 Telomcrase in cancel" therapy 
Successful cancer therapy requires agents that efficiently and specifically kill 
tumour cells but not nonnal cells. Because te!omerasc activity is high in a wide variety 
of human cancers and absent in IllOst nOnlml cells, it might be a plausible target for 
new cancer therapies. Telomerase inhibitors have recently been considered as potential 
antitumour agents. In general, the potential target for inhibiting telomerase activity 
might include: the hTERT active site; the II-base RNA template; the 'anchor site' 
where hTERT interacts with telomeric DNA; the extended telomere, possibly at a G-
quadmplex slnlclure; interacting proteins; or antisense targeting of the mRNA for 
either hTR or hTERT (Pitts and Corey, 1999). There have been several reports on the 
inhibition of telomerase activity in hmlUm celis, including microcell-mediated 
chromosome fusion (Ohmura et ai, 1995), antisense hTR-based approaches (Feng et ai, 
1995 and Bisoffi et aI, 1998), reverse transcriptase inhibitors (Strahl and Blackburn, 
1996), and a telomere-binding protein (Broccoli et al. 1997). Although some of those 
approaches effectively inhibit telomerase activity, it is still 100 early for clinical 
application. Many problcms remain to be resolvcd as, for example, how to taget 
telolllcrase inhibitors specifically to tumour. In addition, the proposed altcrnative 
pathway(s) lIsed by inmlOrtai cells to maintain their telomere might be a limiting 
factor. The key to designing or choosing drugs that will specifically attack telomerasc 
lies in understanding the stmcturc and the mechanism of regulation oftelomerase. 
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1.2 Outline of the present study 
Our studies were undertaken to answer the following questions: (1) At which 
stage in colorectal carcinogenesis is telomcrase activated? (2) What is the relationship 
between telomerase activity and the expression of hTR RNA and hTERT mRNA? (3) 
Is telomerase activated in soft tissue lesions? (4) Can the telomerase assay be used in 
addition to cytological examination in the detection ofneopiastic cells in effusions? 
In chapter 2, a methodological validation of our TRAP assay is reported. As a 
ribonucleoprotein enzyme, tclomerase needs intact RNA as a template and an active 
protein moiety for the reverse transcription of the telomeric TT AGGG repeats. These 
two conditions indicate that the quality of the tissue is of vital importance for a reliable 
telomerase assay. We lise rRNA integrity as a control for the quality of tissue 
preservation. 
In chapter 3, we detennillcd at which morphologically defined step during 
human colorectal carcinogenesis telomerase is activated. In order to establish 
telomerase activation relative to molecular genetic events, K-ras and p53 mutations 
were assayed in the same material. 
In chapter 4, we studied the expression of the telomerase genes (hTR RNA 
and hTERT mRNA) and correlated these with tclomerase activity in human colorectal 
carcinogenesis. Absence of intron sequences is one of the particularities of the hTR 
gene, and the problem of contamination of extracted RNA by genomic DNA for hTR 
RNA analysis by RT -peR was solved by extensive DNase digestion. 
In chapter 5, Telomerase activity has been detected in a majority of human 
carcinomas, but little is known regarding soft tissue sarcomas. We detemlined 
tclomerase activity and hTERT mRNA in a series of soft tissue lesions. Since 
telomerase activation correlates with proliferative activity of cells, we also examined 
this in sarcomas using Ki-67 im1llunolabelling. 
In chapter 6, we tested whether the presence of telomerase activity correlates 
with cytology status in effusions. 
In chapter 7, our findings are discussed in the context of the current literature. 
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ABSTRACT 
Almost without exception, cancer cell lines have tc!oOlcrase activity, which 
does not seem to be the cases for cancer tissues. A possible reason for this apparent 
discrepancy could be false-negative results, due to quality of tissue samples. To tcst 
this hypothesis, we analyzed frozen tissue specimens of 50 colon cancers for 
teiomcrase activity. As RNAs are very easily degradable molecules, we used RNA 
degradation as a parameter of the quality of the tissues. We observed that when the 
RNA was not or only partially degraded in all (25 cases) telomerase activity was 
detected. In contrast, when RNA was highly degraded, 32% of cases (8/25) showed no 
tclomerase activity. We propose that RNA quality control is evaluated as a routine in 
the TRAP assay. 
Telomerase is a ribonucleoprotein with the function of a DNA polymerase, in 
which a segment of the RNA component operates as an intemal template. It adds 
hexameric (TTAGGG) repeats to the teiomeric ends of the chromosomes, thus 
compensating for the continued erosion of the teiomeres that occurs in its absence 
(3,7). Reactivation ofteiomerase may be a necessary event for the sustained growth of 
most human tumors (9). The development of a peR-based tclomerase assay - the 
telomeric repeat amplification protocol (TRAP) - has pennitted a large number of 
tumor samples to be analyzed (5). 
Telomerase activity has been detected in almost all human immortal celt lines 
and in the great majority of human cancer tissues (2,5). Some human tumor tissues, 
however scem not to express teiomerase. A review whieh compiled several studies of 
human tumors indicated that telomerase activity occllrred in human cancer tissues in 
between 75% and 100% of cases, with an average of 84.8% (8). Furthemlore, different 
studies on histologically similar tumors revealed different proportions of tumors with 
telomerase activity. For example, in colorectal cancer tclomerase activity was detected 
in 32 of 35 (92%) by Kim e( al. (5), in 40 of 50 (80%) by Li e( al. (6), and in 8 of 8 
(100%) by Yoshida et al. (I I). An explanation for these discrepancies could be 
heterogeneity of human tumor tisslles : these invariably consist of mixtures of tumor 
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cells and surrounding stromal tissue. However, the TRAP assay has been shown to 
detect telomerase activity in as few as I positive cell per 104 cells (5). We propose that 
some of the apparently negative tumors yield RNA of insufficient quality and are 
therefore false-negative. 
A second reason for false-negative results might be the presence of Taq DNA 
polymerase inhibitors. To recognize this type of problem, the TRAP assay should be 
perfonned using an internal control (10). The TRAPeze kit (Oncor Inc., Gaithersburg, 
:MD) includes the amplification of all internal control of 36 bp in each assay, and a 
false-negative result is concluded when the 36 bp amplified product is not observed. 
This control, however, docs not account for all apparently negative tumor tissues. 
Telomcrase is a ribonucleoprotein enzyme that uses its RNA as a template for 
the synthesis ofTTAGGG repeats at the ends of the chromosomes (4). For this reason, 
telomerase activity necessitates an active protein and a non-degraded RNA. These two 
conditions indicate that the quality of the tissue is of vital importance for the success 
of the telomerase detection assay. Strikingly, RNA quality control has never been 
proposed to date. We therefore included a control for Ri'lA quality in our TRAP assay 
protocol. 
We measured telomcrase activity in 50 colorectal cancer tissues derived from 
50 patients using the TRAP assay (Gncor). About 10 mg of frozen tissue was 
homogenized in ISO ~tl of lxCHAPS lysis buffer. The whole tissue lysate was rapidly 
frozen and stored at -80°C. The protein concentrations of the extract were measured 
using the BCA protein assay kit (Pierce Chemical Corp., Rockford, Illinois, USA). 
About 0.1 ~lg of protein extracted from tissue was used for each telolllerase assay (25 
~tl reaction). Forty two samples (84%) were found to be positive in this assay, while 8 
samples were telomerase negative. All 50 samples were taken from the tissue bank of 
the Institute of Pathology of Lausanne. Some samples were not frozen immediately, a 
relatively important lapse of time occurred sometimes between surgery and freezing in 
liquid nitrogen. Wann ischemia might account for tissue autolysis including RNA 
degradation, which may affect the telomerase activity results. To test this hypothesis, 
total RNA from these 50 colon cancer tissues was extracted using Trizol (Life 
Tedmologies). For each case about 50 mg of frozen tissue was used to extract RNA. 
The quality of RNA was controlled on agarose gels (Figure lA). In 25 out of 50 colon 
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cancer tissues, the RNA showed no or partial 28S and 18S ribosomal RNA 
degradation (Figure lA, lanes 3 to 6). In the other 25 cases significant to complete 
RNA degradation was observed (Figurc lA, lanes 7 to 9). All of the 25 cases with 
only partially degraded or intact RNA showed telomerase activity (Figure lA and IC, 
lanes 3 to 6). Only 17 of the 25 (68%) cases with strongly or complete degraded RNA 
were positive for telomemsc activity (Figure 1 A and I C, lanes 7 to 9). This difference 
is statistically significant (p<O.OOOl). Various levels of telomerase activity was 
observed. All the 25 cases with only weak RNA degradation showed strong telolllerase 
activity (Fig I C, lanes 3 to 6), whereas a majority of cases with strongly degraded 
RNA had either weak (Figure IC, lanes 7 and 8) or even no (Figure IC, lanes 9 and 
10) telomerase activity. Almost all the cases with complctc RNA degradation had no 
detcctable telomerase activity (Figurc IA and IC, lanes 9 and 10). The fact that 
tclomerase activily was observed in somc cases with apparent RNA degradation could 
bc explained on the assumption that full length of the RNA component of telomerase 
is not necessary for telomerase activity (l). Another explanation for the presence of 
telomerase activity in partially degraded samples could be the sensitivity of the TRAP 
assay. Indeed, even an important reduction in the number of active telolllerase 
molecules due to tissue degradation may not totally abolish detectable teloll1crase 
activity in the sample. 
A limitation of this approach is that the amount oftissuc required to perfonll an 
rRNA measurement is too high for small biopsies. To overcome this limitation, 
different approaches have been testcd. First, RNA quality was determined directly 
from the RNA in tissue extracts obtained from CHAPS lysis buffcr. Using Trizol, 5-10 
~tg of total RNA was obtained from tissue extracts (60 ~lg of protein extract). Some 
rRNA degradation was observed by agarosc gel analysis, and in a majority of cases no 
28S and I8S ribosomal RNA bands were observed. The same RNAs were also 
analyzed by RT -PCR using p-actin and GAPDH as markers. Almost all cases gave an 
amplification of J3-actin and GAPDH, even in the cases where telomerase activity was 
undetectable. RT-PCR gavc many false-positive results and is therefore not a suitable 
method to detemline tissue quality. In another approach, total RNA was extracted from 
consecutive tissue sections. Depending on the size of the tissue sample to analyze, 1-5 
sections of 10 ~M are enough to extract cells in 30 ~t1 of CHAPS lysis buffer for 
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telomerase analysis, whereas 4~ 10 sections arc necessary for extraction of a sufficient 
amount of RNA (total RNA dissolved in 20 ~t1 water). Using this approach, the results 
for telomerase activity and rRNA measurements are perfectly superimposable with 
those obtained with large amount of tissues (Figure I A and iB for rRNA quality). 
Furthemlore, sections for histological analysis can be prepared just before and after the 
section necessary for teiomcrase and RNA analysis. Thus, histological characteristics 
of the analyzed lesions can be correlated directly to telomerase activity and false~ 
negative results due to sampling error can be avoided. 
These results indicate that if RNA is not strongly or completely degraded (2SS 
and iSS ribosomal RNAs species not completely lacking) more reliable results will be 
obtained. If RNA is strongly degraded, telomerase activity is not always observed 
(Table 1). Our results clearly indicate that for a valid TRAP assay, the control of RNA 
quality is essential in order to I'edtlce the number of false~negative results. This control 
is simple and rapid (can be done in less than 2 hours). 
Table 1. Telomerase activity and RNA degradation 
in olorectal cancer tissues 
Telomerase+ 
Telomerase -
RNAi 
25 
o 
RNAd 
17 
8 
RNAi: RNA intact or only partially degraded 
RNAd: high RNA degradation (2SS and ISS ribosomal 
RNAs species completely lacking) 
30 
A 
B 
c 
+--28$ 
+--18s 
Telomeras.e 
pro"",,' 
Internal control 
36", 
Figure 1. RNA quality and telomerase activity in coloredsl cancer tissues. (A+B) Total RNA 
extracted from frozen colon cancer tissues (A) and from tissue sections (B) was subjected to 1% agarose 
gel electrophroresis. Lanes 2 to 10 contained about 0.6-1.0 ~Ig ortola! RNA .. (C) Telomemsc activity 
was detected using the TRAP assay from Oneor. About 0.1 ~tg of protein extracted from frozen colon 
cancer tissues was placed in 25 pi of peR reaction mixture for each assay. One of fifth of peR 
amplification product was applied to a 12.5% non-denaturing polyacrylamide gel electrophoresis and 
visualized by SYBR green I staining. Lane I: pGEM DNA marker (promega). RNA analysis (part A+B) 
or telomerase assay (part C) from SW480 coloreela! cancer cell line (lane 2) or from frozen coioreclal 
lumor tissues (lanes 3-IO).l.anell, part C: negative control where no protein was added. 
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SUMMARY 
Telomcrase activity has been detected in germ cells as well as in the 
developing embryo. Activity is no longer detectable in 1110st somatic cells of the 
neonate, although low levels of activity persist in regenerative tissues. Telomerase has 
been found to be reactivated or upregulatcd in a majority of cancers. The colorectal 
adenoma-carcinoma sequence is one of the best characterised models of multistep 
tumorigenesis, and thus suitable to detenninc at which stage telomerase is activated. 
Telomerase activity was examined by telomcric repeal amplification protocol (TRAP) 
assay in 96 cases of colorcctal tissues, including 50 carcinomas, 31 adenomas and 15 
nomlal colon tissues. For each case, histological diagnosis and telomerase activity 
were detennined on consecutive frozen sections. In order to reduce the chance of a 
f.'llse-negative TRAP assay due to RNA degradation, the integrity of rRNA in the 
tissues was verified in each case. Twenty five carcinomas, 30 adenomas and all oflhe 
15 nonnal colorectalmucosa samples showed no or only partial rRNA degradation and 
only in these cases the TRAP assay was interpreted. None of the nornlal tissues 
exhibited telomerase activity. In contrast, all of the 25 cancers and 47% (14130) of the 
adenomas were positive. In adenomas, teiomerase activation was highly significantly 
related to grade of dysplasia (P<O.OOOI). All adenomas which contained HG dysplasia 
revealed telomerase activity, whereas in only 20% (4/20) of cases with exclusively LG 
dysplasia telomerase activity was detectable. Our results indicate that telomerase 
activation, which might be an obligatory step in colorectal carcinogenesis, occurs in 
the progression from low grade to high grade dysplasia in adenoma. Furthennore, in 
the adenoma~carcitloma sequence teiomerase activation seems to occur later than K ~ 
rclS mutation but earlier than p53 mutation. 
Key words: Telomcrase, TRAP assay, Colorectal carcinoma, Colorcctal adenoma, K~ 
ras mutation,p53 Illutation 
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INTRODUCTION 
The telomerc-telomcrase hypothesis of cell aging has rapidly become a focus 
of intensive research in the field of carcinogenesis. The hypothesis is based on the 
observation that telomerase activity is expressed in embryonic cells, in adult geml1ine 
cells (1, 2), and in most human tumours (1, 3), but is undetectable in l1onna1 somatic 
tissues except fOf proliferative cells of renewable tissues including haemopoietic stem 
cells (4, S, 6), activated lymphocytes (4), basal ceJls of the epidennis (7, 8) and 
intestinal crypt cells (9). Human teloll1cres, which are composed of many kilo bases of 
TTAGGG repeats and associated proteins, protect and stabilize chromosome ends 
during DNA replication (l0, 11). In nonnal somatic cells telomcric DNA is lost with 
each cell division, because DNA polymerases synthesise DNA in the 5' to 3' direction 
and require an RNA primer for initiation. The end replication problem (12) predicts 
the progressive loss of telomeric DNA. Thus, telomere reduction is thought to be a 
biologic clock regulating the life span of a cell. In contrast to nonnal cells, tumour 
cells show no loss of average telomere length with cell division, suggesting that 
telomere stability may be required for cells to escape from replicative senescence, and 
thus can proliferate indefinitely. This telomere length stability appears to be the 
consequence of telomerase activation. It is likely a necessary event for sustained cell 
growth in malignant tumours. Telomerase, a ribonucleoprotein complex, is a 
specialised reverse transeriptase that synthesises telomcrie DNA sequences and thus 
restores telomere length (13,14). 
Telomerase activity has been found in almost all human cancer tissues and 
cancer cell lines tested to date (t5). However, at which moment in the multistep 
pathogenesis of cancer telomerase is activated rcmains to be clarified. If telomerase 
could be used to detect preinvasive neoplasia, this could then be treated with greater 
efficiency and lesser toxicity than invasivc canceL So, early detection based on 
telomerase activation assays might have the potential to reduce cancer morbidity and 
mortality. 
The colorectal adenoma-carcinoma sequence is one of the best characterised 
models for multistep tumorigenesis. Progression from adenoma to carcinoma has been 
shown to occur along with stepwise accumulation of distinct genetic alterations, each 
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new alteration contributing to progression of the lesion through clonal expansion of a 
cell with a new altcration which confers a growth advantage (16). Tissue samples from 
different stages can be obtained relatively easily which allows charactcrisation of the 
histopathological steps and accompanying genetic alterations. Telomerase activity has 
been found in 90-95% of stage I colon carcinomas, but at present its presence in 
adenomas has not been unambiguously established. Some authors have indicated that 
telomcrase is activated in colorectal adenomas, but at a low levcl (17). Others have 
reported absence of tclomerase activity in colorectal adenomas (I, IS). As pointed out 
by Meeker and Coffey (19), thcre are lllany pitfalls in assaying telomerase activity, 
including inadequate handing of samples, sampling artefact, contamination with active 
material and peR inhibitors. For tllis reason, it is quite important to use proper 
positiye and negative controls. Another reason for conflicting results, could be the 
occurrence of heterogeneity within colorectal adenomas. In a previous study, we have 
shown that genetic and histopathologic heterogeneity occurs in a grcat majority of 
colorectal adenomas (20). This finding underlines that pathological characteristics and 
te10merase activity should be compared on several sections taken from the same tissue 
sample, to allow for adequate histological infonnation. 
The aim of our study was to detennine at which morphological steps during 
human colorectal carcinogenesis telomerase is activated under experimental conditions 
allowing an appreciation of RNA integrity and assessment of the degree of dysplasia 
in the tissue fragment assayed for telomerasc. Telomerase activity was detected by the 
TRAP (telomeric repeat amplification protocol) assay (21); which is a sensitive, 
reliable and reproducible test, when suitable controls are included (19). In order to 
established telomerase activation relative to molecular genetic events, K~ras and p53 
mutations were assayed in the same material. 
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MATERIALS AND METHODS 
Patients alld Tissue Samples 
Tissue samples from 50 surgically resected colorectal. carcinomas were 
obtained from the tissue bank of the Institute of Pathology of Lausmme. Thirty 
colorectaI adenomas were obtained by colonoscopic polypectomy. The size of polyps 
was measured immediately upon reception of the samples. Peripheral slices of the 
polyps were immediately embedded in OCT, frozen in liquid nitrogen, and stored at ~ 
80°C until use. From 15 nOll-cancer related colectomy cases, apparently nannal colon 
mucosa was sampled and frozen as described. 
Sample Preparatioll 
From each colorcctal case, a thin piece of tissue was sampled for DNA 
extraction. Then, 10-15 consecutive cryostat sections were Clit. The first and the last 
sections were H&E stained in order to assess histological characteristics. The sections 
in between were cut at 12 ~lIn and put into two chilled 1.5 Illl Eppendorf tubes using a 
tapered glass pipette. Depending on the size of the tissue sample, 1-5 sections were 
sufficient to extract protein in 30 ~tl of CHAPS lysis buffer for the detection of 
telomerase activity, and 5-10 sections were necessary for extraction of a sufficient 
amount of total RNA. 
Histological assessmelll of dysplasia ill lite sample 
H&E stained cryostat sections were reviewed by two pathologists (ES, HB). 
For histological diagnosis and grading of dysplasia, thc criteria of the \Vorld health 
organisation (23) and of the National Polyp Study Group (24) wcre used. According to 
the degree of dysplasia, adenomas were grouped into low-grade (mild and moderate) 
and high-grade (scvere dysplasia and in situ carcinoma, confined to the mucosa) 
categories. The grade of dysplasia was established according to the most severely 
dysplastic area. Furthennore, the proportion of the high-grade dysplasia (HG) was 
established by semi-quantitative scoring and this allowed us to classify the cases into 
three groups: (LG) adenomas with low grade dysplasia only; (LG+HG) adenomas 
with low grade and high grade dysplasia, when HG was present in 1-50% of the 
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section; (HG) adenomas with high proportion of high grade dysplasia, when HG 
dysplasia was present in more than 50% of the sample. 
COl/trol 0/ RNA degradation 
Total RNA was extracted from tissue sections using Trizol (Life Teclmology), 
and after ethanol precipitation in presence of 1 O~tg glycogen redissolved in 20 ,...1 of 
RNase·free water. About 0.6 ·1.0 ~lg of total RNA was subjected to 1% agarose gel 
electrophoresis. When 28S and/or I8S ribosomal RNA (rRNA) bands appeared on the 
agarose gel, rRNA was judged intact or partially degraded. If no 28S and 18S rRNA 
bands were present, rRNA was judged totally degraded (22). 
TRAP assay/or Telomerase Actil'ity 
Telomerase activity was detennined lIsing the TRAP assay according to 
manufacturer's protocol of the TRAPeze Telomerasc Dctection Kit (Qncor). For the 
colorectal carcinoma cell line SW480, cell peliets (about Ix IOscel\s) were suspended 
with 400 ,...1 of CHAPS lysis buffer. For frozcn tissues, 1·5 sections were 
homogenised with 30 ~II of CHAPS lysis buffer. Aller incubation for 30 min on ice, 
the lysate was centrifuged and the supematant was stored at ·80°C immediately. 
Protein concentration of the extract was measured by the BCA protein assay kit 
(Pierce Chemical Corp., Rockford, Illinois, USA). For each case the TRAP assay was 
perfonned in three different concentrations of protein extracts: 0.1, 0.5 and 1 J..tg. The 
TRAP reactions (25 ~II final volume) contained IxTRAP buffer, 50 mM dNTPs, 0.5 
,...1 ofTS primer, 0.5 ~tl of TRAP primer mix, I unit Toq DNA polymerase (Boehringer 
Mannheim) and an aliquot of CHAPS cell extract (I, 0.5 or 0.1 ~lg of protein extract). 
The extract of colorectal carcinoma cell lines (equivalent to 250 cells) was used as a 
positive control in the telomerase assay. TRAP reaction mixture was placed in a 
thennocycler and incubated for 30 min at 30°C. 94°C for 2min, then 32 cycles of 94°C 
for 30 s, 56°C for 45 sand noc for 45 s were perfomled. PCR products (5 ~II) were 
electrophoresed on a 12.5% polyacrylamide nondenaturing gels. The gels were stained 
with SYBY green I (FMC Bio Products) and visualised under UV light using a CCD 
camera. 
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Detection 0/ K-ras ami p53 Mutations by NOIl-rafiioactiJ'e Single Stralld 
COli/ormation Polymorpldsm (SSCP) 
Genomic DNA was extracted from samples using standard methods. Exon I of 
K-ras and exons 5 to 9 of p53 genes were amplified by PCR. The PCR reaction was 
carried out for 35 cyclcs using the following amplification profile: denaturation at 
940 C for 30 sec, annealing at 54-600 C for 45 sec, and extension at noc for 45 sec. 
Correct amplification was controlled by electrophoresis on a 2% agarose gel. Five to 
forty ng of PCR product were then analysed by non-radioactive SSCP as described 
previously (20,25). 
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RESULTS 
Telomerase Activity ill colorectallissfles 
By analysis of ribosomal RNAs (rRNA), we found that only 25 of the 50 
colorectal cancer tissues had intact or only partially degraded rRNA, the other 25 cases 
showing highly degraded rRNA. This is most likely due to the surgical procedure, in 
which the early ligation of the perfusing vasculature might be responsible for a 
relatively long preoperative wann ischemic period. This explanation is consistent with 
the fact that only one adenoma and no Hannai colorectal mucosa samples showed 
rRNA degradation. Amplification using the TRAP*cze kit resulted in the [omlation of 
a 36-bp band in every lane (Fig. 1), which served as an intemal control to identify false 
negatives due to the presence of Taq polymerase inhibitors. In our senes, all samples 
demonstrated a 36~bp band. All of the 25 cases of colorcelal cancer with only partially 
degraded or intact rRNA contained telomerase activity. Only 14 out of30 (47%) cases 
of adenoma, with no or only very partially degraded rRNA, exprcsscd teioll1crasc 
activity. No telomerase activity was found in 15 Bonnal colon mucosa samples (Table 
1). 
Table 1. Tetomerase activity in colorcctal tissues 
No of positive eascs/ % positive 
No of cases 
Colorectal carcinoma 25125 100 
Colorcctal adenoma 14/30 47 
Nomlai colorectal B1l1COsa 0115 0 
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Figure 1: Telomerase activity in coloreclal tissue-so From each tissue sample, lelomerase assays were 
perfomled by the TRAP method using extracts containing 0.1, 0.5 or I )1g of protein (lanes 3-14). The 
extract of the human colorectal carcinoma cell line SW480 (equivalent to 250 cells) was used as a 
positive control (lane 2). The 36-bp internal positive control band was seen in eve!), lane, and it was 
used to identify non-infonnative specimens due 10 inhibitors of Taq polymerase. A size marker. pOEM 
DNA marker (Promega), was also shown in lane l. 
Correlatioll with Histopatofogical Characteristics alld Tefomerase actb'ity ill 
colorectaf adenomas 
Telomerase activity was detected in 35% (7120) of adenomas with a size 
smaller than 2 cm and in 70% (7/1 0) of adenomas larger than 2 cm; but this difference 
is not statistically significant. No correlation was observed between the presence of 
telomerase activity and architecture of the adenomas (Table 2). 
Histopathological analysis of the adenomas, showed LG dysplasia (LG) in 20 
cases, less than 50% HG dysplasia (LG+HG) in 4 cases, and morc than 50% 
HG dysplasia (HO) in 6 cases. Telomerasc activity was significantly correlated with 
the grade of dysplasia in the assayed tissue sample (P<O.OOOl). Telomerase activity 
was present in all of the adenomas with HG dysplasia (10 cases) and in only 20% 
(4/20) of the adenomas which did not contain HG dysplasia (Table 2). 
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Table 2. Correlation between telomerase activity, K-ras mutation and histology 
in colorectal adenomas 
Telomcrase Telomcrase 
No of cases pa 
positive negative 
(%) (%) 
Size: 
0.8 - 2 em 7 (35%) 13 (65%) 20 0.07 
> 2 em 7 (70%) 3 (30%) 10 
HJstology 
Tubular 7 (54%) 6 (46%) 13 
Tubulo-villous 5 (38%) 8 (62%) 13 0.72 
Villous 2 (50%) 2 (50%) 4 
Dysplasia h 
LG 4 (20%) 16 (80%) 20 <0.0001 
HG 10(100%) 0 10 
K-ras Illutation 
Negative 6 (38%) 10 (62%) 16 0.28 
Positive 8 (57%) 6 (43%) 14 
Total cases 14 (47%) 16 (53%) 30 
a chi-square test, 
b LG: low grade dysplasia only; HG: high grade dysplasia. Grade of dysplasia 
was established in the same sample where telomerase activity was assessed. 
One HG sample was devoid of detectable telomerase activity by the standard 
TRAP assay (Table 3, case 21). To elucidate whether absence of telomerase activity 
was not due to degradation of teiomerase RNA component, a ribonuclease inhibitor 
was added during the process of protein cell extraction. The ribonuclease inhibitor 
(RNasin from Promega, Madison \VI) was used at a concentration of 0.3 U per ~Il of 
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CHAPS lysis buffer. As expected, a weak teiomerase activity was recovered. 
Telomerase negative adenomas with only LG dysplasia were also tested for presence 
of RNase, but none of them revealed telomerase activity even when RNasin was 
previously added to the cell extract. 
Telomerase activity, K-ras alld p53 IJllltlltiOIlS ill colorectal adellomas alld 
carciJlomas 
In 14 of 30 (47%) adenomas a K-ras mutation was observed in the same area 
of the adenoma where telomerase activity was measured (Table 2 and 3). In our series, 
the proportion of adenomas and carcinomas with a K-ras mutation were very similar, 
47% and 48% respectively. The frequency of K-ras mutations seems to increase with 
either the grade of dysplasia or presence of teiomerase activity (Table 3). Six of 10 
(60%) of adenoma samples with HG dysplasia but only 8 of 20 (40%) adenoma 
samples with LG dysplasia harboured a K-ras mutation, but this difference did not 
attain statistical significance. In the same manner, no positive correlation between 
increased telomerase activity and K-ras mutation has been observed. As expected, 
p53 mutations were more predominant in cancers than in adenomas, respectively 40% 
and 10%. Only 3 (10%) adenomas harboured a ])53 mutations and this genetic 
alteration was observed in low grade as well as in high gradc adenomas (Table 3). 
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Table 3. Tclomerase activity, histological characteristics and genetic alterations 
in colorectal adenoma 
Case Size Typea Grade of %HG Telomerasc K-rasd p53d 
No (elll) dysplasia dysplasia activityC 
<I V LG 0 wI wI 
2 <I T LG 0 + 12-GAT wI 
3 1-2 T-V LG 0 wI wI 
4 1-2 T-V LG 0 wI wI 
5 1-2 T LG 0 12-GAT wI 
6 <I T LG 0 + 12-GAT wI 
7 <I T LG 0 wI wI 
8 <I T-V LG 0 wI exoll 8 
9 1-2 T-V LG 0 wi wI 
10 >2 V LG 0 + wI wI 
II >2 T-V LG 0 12-GAT wI 
12 >2 T-V LG 0 + wt wi 
13 >2 T-V LG 0 12-GAT wt 
14 1-2 T-V LG 0 wI wI 
15 1-2 T LG 0 wI wI 
16 1-2 T LG 0 12-AGT wt 
17 >2 V LG 0 12-GAT wI 
18 1-2 T LG 0 12-GAT wI 
19 1-2 T-V LG 0 wt exon 8 
20 <I T LG 0 wI wI 
21 <I T LG+HG 3 +' wt wI 
22 1-2 T LG+HG 10 + 13-CGC wI 
23 >2 T-V LG+HG 10 + wt wI 
24 >2 T-V LG+HG 10 + wi wt 
25 1-2 T HG 60 + w wI 
26 >2 V HG 60 + 12-TGT wi 
27 >2 T-V HG 80 + 12-AGT exon 7 
28 1-2 T HG 80 + 12-GTT wI 
29 1-2 T-V HG 80 + 13-GAC wI 
30 >2 T HG 90 + 13-GAC wI 
a T= tubultous adenoma; T-V = tubuJlo-villous adenoma ; V = villous adenoma 
b LG, low grade dysplasia; LG+ HG. low grade dysplasia with <50% of high grade 
dysplasia; RO, ;::>:50% high grade dysplasia. 
C Telomerase activity assayed by TRAP. 
d K-ras andp53 mutations detected by SSCP. 
e Positive by TRAP only when a ribonuclease inhibitor was added during cell extract 
preparation. 
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DISCUSSION 
Teiomcrase activity is found to be activated or upregulated in a majority of 
human cancers (15,19). There is some evidence that telomerase activity is present 
early in some specific cancers (26-30), but conflicting results have been reported in 
eoloreetal tumorigenesis (I 7, 18). To date, it is still unclear at which slage of colorectal 
carcinogenesis telomerase is activated and whether or not telomcrase activation might 
be indicative of malignant potential in a colorectal adenoma. We therefore studied 
telomerase activity in colorectal carcinomas (25 cases selected for intact rRNA), 
colorecta! adenomas (30 cases) and nannal COI0I1111UCOSa (15 cases). We found that all 
carcinomas and 47% (14/30) of the adenomas expressed the enzyme; telomerase 
activity was not detected in nonnal colon tissues. 
TeIomerase activity has been detected in aImost all human cancer cell lines 
and in the vast majority of human cancer tissues (15). Nevertheless, in about lO%~15% 
of the reported human cancers telomerase activity was not detected (I). In principle, 
for seemingly telomerase negative cases several explanation should be considered. 
Firstly, teIomerase independent mechanisms for the conservation of telomere length 
should be considered (31). These most probably exist but this remains elusive as yet. 
Secondly, telomerase might remain undetectable due to technical problems such as 
polymerase inhibitors or degradation of the enzyme complex. The latter problem has 
been overlooked but appears to be quite important. Of our colorectal cancer samples 
with undegraded rRNA 100% (25 cases) were telomerase positive, whereas only 64% 
(160[25 cases) of the samples with degraded rRNA showed telomerase activity. This 
difference is statistically significant (P<O.OOOI). This observation clearly indicates that 
the integrity of RNA is an important detenninant of the TRAP assay results. In fact, 
even slight degradation of the cell sample could lead to inactivation of the telomerase 
complex. Degradation of RNA is most likely not a result of flaws in the tissue 
collection protocol but related to the surgical npproach, in which early ligntion of 
perfusing vessels (in order to limit liberation of tumour cells into the circulation) may 
be responsible for a relative long peroperative waml ischemic interval. We contend 
that telomerase activity would be detected in almost if not all coloreetal carcinomas 
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provided that the tissue samples are adequately preserved. If so, telomerase re-
activation can be regarded as an obligatory step in colorectal carcinogenesis. 
Telomerase activity was also studied in colorcctal adenomas and in nonnal 
colorectaI mucosa, Of the adenomas 47% (14/30) had detectable telomerase activity, 
whereas no such activity was found in histologically !lomlal mucosa, The degree of 
dysplasia in the sample assayed for telomerase activity was highly significantly 
correlated (P<O.OOOI) with telomerase activation. All adenoma samples with HG 
dysplasia revealed telomerase activity, whereas only 20% of the adenomas samples 
with only LO dysplasia showed telomerase activity, generally at a lower level than in 
adenomas with HO dysplasia. Our reslills would indicate that telomerase activity is 
activated in adenoma at the stage of low grade dysplasia and present in all the areas 
with high grade dysplasia. They also suggest that teiomerase positive LG dysplastic 
adenomas have a higher risk to progress towards HG dysplastic adenoma and 
colorectal carcinoma than do those without telomerase activity. 
In the currently favoured model of colorectal carcinogenesis (16,32), APC 
Illutations initiate the neoplastic process and the lesion progresses through 
accumulation of additional genetic alterations, implicating oncogenes and tumour 
suppressor genes (Fig. 2). K-ras Illutations occur very early in 35%-45% of colorectal 
adenomas regardless of the degree of dysplasia and carcinomas (33,34). LOR of 18q, 
which might imply loss of fUllction of Dee or DPC4, occurs in 50%-80% of HG 
adenomas, whereas p53 mutations are limited in adenomas and occur in up to 70% of 
carcinomas (35,36). In our series, telomerase activation and K-ras mutation were not 
correlated; K-ras mutations occurred at a similar level in adenomas with or without 
HG dysplasia, which indicates that teiolllerase activation is a later event than K-ras 
mutation. Conversely, teJomerase activity occurred with similar frequency in cancers 
and in adenomas with HG dysplasia. This would place telolllerase activation before 
p53 mutation in the molecular carcinogenetic concept of the adenoma-carcinoma 
sequence (Fig. 2). 
In conclusion, we have demonstrated that under appropriately contTOJIed 
conditions 100% ofcarcinolllas and adenomas with HG dysplasia, but only 20% ofLG 
dysplastic adenomas, show tel om erase activity. Telomerase activation therefore 
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appears to be an essential step in the progression from a low grade to a high grade 
adenoma, 
APC K-I"us Telontcrase aclil'ation p53 
Other 
Changes ? 
Figure 2: Genetic pathway of colorectal carcinogenesis, TIlis model proposed by Fearon and 
Vogelstein is based on the concept of an adenoma·carcinoma sequence. All the molecular genetic 
allerations shO\\1l in this model rarely occur together in an individual. According to our resulls, 
telomCnlse activation will occurred between low grade to high grade dysplasia in adenomas with a very 
high frequency. ACF: aberrant crypt foci. 
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SUMMARY 
The human telomerase enzyme is composed of two essential components, hTR, 
which acts as a template for reverse transcription, and hTERT, which is the putative 
catalytic subunit for the enzyme. Recent studies have demonstrated a good correlation 
between hTERT expression and telomerase activation, whereas RT-PCR results 
seemed to reveal that hTR is ubiquitously expressed in all cells. These observations 
left unclear the role of hTR, and to a lesser extent hTERT, in the regulation of 
telomerase activation. In the present study, we examined the correlation of tclomerase 
activity and the expression of these genes on a total of 70 colorectal tissues (25 
adenocarcinomas, 30 adenomas and 15 HonnaI colorectaI ll1ucosas).ll1 our series, total 
RNA for RT-PCR analysis and cell extract for TRAP assay were obtained from 
consecutive sections and histological control was simultaneously performed. To avoid 
false-positive results, due to the fact that hTR cDNA and genomic hTR DNA are 
identical (the gene has no introns), extensive DNase digestion was perfomlcd before 
cDNA synthesis. RT-PCR analysis revcaled hTERT mRNA to be expressed in all 
cancers and in 13 of 14 telomerase-positive adenomas, but never in telomerase-
negative colorectal tissues. hTR transcripts were observed in all telomerase positive 
samples but also in 3 telomerase-negative samples, two adenomas and one nonnal 
colon mucosa. We conclude that hTERT and hTR expression are strongly correlated 
with telomerase activity. hTR transcripts, howevcr, occur also in some telomerase 
negative tissues, and our results are in keeping with the concept that hTERT 
expression is a major regulator oftelomcrase activity. 
Key words: Telomerase, Colorectal Carcinogenesis, RT-PCR, TRAP assay, hTERT, 
hTR. 
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INTRODUCTION 
Telomerase, a ribonucleoprotein that catalyses the addition of TTAGGG 
repeats to the end of vertebrate chromosomes, is expressed in geml celis, in stem celis, 
in tumour ceJllincs and in the majority of tumours, but generally not in somatic cells 
(1-3). Telomerase reactivation might be a prerequisite for the development of 
malignant tumours from somatic cells. In humans, three major genes are responsible 
for the activation of telomcrase: the human telomcrase RNA (hTR), the tclomerase 
associated protein (TPl) and the human telomerase reverse transcriptase protein 
subunit (hTERT). These teiolllcrase component genes have been characterised recently 
(4-6). 
TPI, of which the function as yet remains unknown, does not reflect the level 
of telomerase activity and is ubiquitously expressed (7,8). Thus, TPI does apparently 
not playa cmcial role during telomerase activation. II might be required ill vivo for full 
telomerase assembly, function and regulation, but it C~lIl not be used as an indicator of 
telomerase activation. 
hTR acts as a template for telomere elongation by the reverse transcriptase 
subunit. In an ill vitro reconstitution experiment of human telomerase activity, hTR 
appeared to be an essential component (9). Tumour cells transfected with antisense hTR 
loose telomeric DNA, resulting in cellular senescence (4). 1l1ese findings confiml that 
hTR is indispensable for telomerase activity. Whether or not hTR expression is an 
indicator of telomerase activity is a controversial issllc. A correlation has been found 
between telomerasc activity and hTR expression, as detennined by in situ hybridisation 
(10-13). Recent studies, however, demonstrated that hTR RNA, as detected by RT-PCR, 
is widely expressed in both cancer and non-cancer tissues, although in cancer tissue at a 
higher level (7,8,10,14,15). The fact that the hTH. genc has no introns requires specific 
consideration. hTR cDNA is identical to genomic hTR DNA and, as it is very difl1cult to 
avoid the prcsence of traces of genomic DNA in extracted RNA, during peR 
amplification genomic hTR DNA might be co-amplit1ed, leading to false-positive results. 
nlis might explain why, by RT-PCR, hTR RNA has been found in cancer and non-cancer 
tissues, irrespective of telomcrase activity. 111is problcm can be circumvented by 
extensive DNase digestion of the extracted Rl'J"A before eDNA synthesis. Very few RT-
peR experiments were perfonned with the lise of DNase before eDNA synthesis (24-
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27). In a recent report, nonnal urine samples were analysed and hTR was detected in 
only 15% of them whereas 83% of the urine samples from the patients with bladder 
cancer were found hTR-positive (24). In gastric tissues, Yasui et al have observed that 
telomerasc activity was associated with inereased hTERT and hTR expression (25). 
Unfortunately, in the other two papers, no nonnal tissues were analysed (26, 27). 
hTERT has been identified as the putative human telomerase catalytic subunit (6). 
The expression of hTERT is closely correlated with telomerase activity ill vitro and ill 
vim (6,16). Transfection of foreskin fibroblasts and retinal epithelial cells with plasmids 
encoding hTERT resulted in teiol11erase activity, telomere maintenance, and extension of 
life span (17,18). Regulation of the hTERT expression has been proposed as the major 
detemlinant of the regulation of teioIllerase activity. hTERT mRNA, as detennined by 
either RNase protection or RT-PCR analysis, appears to be expressed at high levels in 
human tumours, cancer cell lines, and nonnal telomerase-positive tissues, but absent in 
telomerase-negative cell lines and in telomerase-negalivc tissues (6,15,16). Kolquist 
found hTERT mRNA by in situ hybridisation not only in carcinoma tissues but also in 
proliferative cells ofnomlal tisslles. Unfortunately, telomerase activity was not assayed in 
thisstudy (19). 
In a previous study, we have demonstrated that telomerase activation occurs in 
the progression from low grade to high grade adenoma (20). In the present study. the 
expression of hTERT mRNA and hTR RNA was detennined by RT-PCR during 
colorectal carcinogenesis in order to delennine which of these components might be 
primarily responsible for the regulation oftelomerase activity. 
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MATERIAL AND METHODS 
Tissue samples and TRAP assay 
A total of 70 tissue samples were used in this shldy, including 25 colorectal 
carcinomas, 30 coloreclal adenomas and 15 samples of nomlal colon mucosa. 
Adenomas were divided into two groups: adenomas with low grade (LO) dysplasia 
only; adenomas with at least focally high grade (HG) dysplasia. All tissue specimens 
were serially sectioned. The first and the last sections were cut at 5 ~un and stained 
with hematoxylin and eosin for conventional microscopic examination by two 
independent pathologists. Telomcrase activity and the presence of hTR RNA and 
hTERT mRNA transcripts were detennined on protein and total RNA extract from the 
intennediatc 12 ~Ul1 sections. In a previous study, telomerase activity had been 
detennined by the TRAP assay in the same samples (20). Briefly, depending on the 
size of the tissue sample, for each colorectal case 1 to 5 sections were sufficient to 
extract protein in 30 ~tI of CHAPS lysis buffer. Telomerase activity was detennined 
using the TRAP assay according to IlHlllUh1cturer's protocol of the TRAPeze 
Telomerase Detection Kit (Oncor, Gaithersburg, MD, U.S,A,) and with three different 
concentrations of protein extracts: 0.1, 0.5 and 1 ~lg. 
RNA preparatioll 
Total RNA was extracted from tissue sections using Trizol (Life Technology) 
and, after ethanol precipitation in presence of 1 0 ~lg glycogen, resuspended in 20 ~tl of 
RNase-free water, About 0,6 to 1.0 Ilg of total RNA was subjected to 1% agarose gel 
electrophoresis. Good RNA quality was judged when 28S and/or 18S ribosomal RNA 
(rRNA) bands appeared on the agarose gel (21). Only the tissue samples with good 
RNA quality were used in our series, 
To eliminate contaminating DNA, 5-10 ~lg of RNA was exposed to RNase-free 
DNase I (l U/~tg Rt'JA, Roche Diagnostics, Gennany) at 37°C for 30 minutes in 40 ~l 
ofa solution containing 40 mM Tris-HCL (pH7,9), 6m~\!1 J."lgCI1, IOmM eaCll , IOmM 
NaCl, 10 mM DTT and 4U RNasine (Promcga, rVladison WI ). The digestion was 
stopped by addition of 5 ~t1 of a stop-solution (50mM EDT A and L5M Na-acetatc), 
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The DNA-free RNA solution was re-extracted with phcnol-chlorofoml and 
precipitated in ethanol in presence of 10 j..tg glycogen. 
eDNA sylllhesis alld peR 
cDNA was obtained from 2-5 ~lg of total RNA (treated or not with DNase) 
using Expand Reverse Transcriptase (Roche Diagnostics, GemlatlY) and d(N)6 random 
primers as per manufacturer's inslnlctions, For each sample, a parallel RNA was run 
with no Expand RT, 
Two microliters (1/10) of the resulting cDNA was subjected to peR, in a total 
volume of 20 Jl1, with the primers as follows: hTERT, 5'-
TTCCTGCACTGGCTGATGAGTGT and 5'-CGCTCGGCCCTCTTTTCTCTG hTR, 
5' -CGCCGTGCTTTTGCTCC and 5' -ACTCGCTCCGTTCCTCTTCC; p53 5'-
TCTGGGCTTCTTGCATTCTGGGACA and 5'-
TCTCGGAACATCTCGAAGCGCTCA; GAPDH 5'-
GGGAAGGTGAAGGTCGGAGTC and 5' -AGCAGAGGGGGCAGAGATGAT. The 
amplification reactions were perfonned with an initial incubation step at 95°e for 5 
minutes followed by 40 cycles at 94°e for 30 seconds, 65°C for 45 seconds, and noe 
for 45 seconds for hTERT; 35 cycles at 94°C for 30 seconds, 58°C for 45 seconds, and 
noe for 45 seconds for hTR; and 30 cycles at 94°C for 30 seconds, 62°e for 45 
seconds, and noe for 45 seconds for p53 and GAPDH, with a final incubation at noe 
for 10 minutes for all cDNAs. The reaction products were sUbjected to electrophoresis 
in 1.5 % agarose gel and visualised by ethidiulll bromide staining, The peR procedure 
was perfonncd at least twice for each sample. 
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RESULTS 
RT-PCR analysis revealed the presence of hTERT mRNA in al1 25 colorcctal 
carcinomas, 9 of lO (90%) adenomas with HG dysplasia and 4 0[20 (20%) adenomas 
with LG dysplasia (Table. I and Fig. 1). All but olle of these samples were also 
telomcrase positive. In only one case, an adenoma with HG dysplasia, the TRAP assay 
was positive but rio hTERT mRNA could be detected by RT-PCR. No hTERT mRNA 
was found in 15 tclomerase negative samples of nonnal colon mucosa. Therefore, 
expression ofhTERT mRNA and tclomerase activity coincided almost perfectly. 
+- hTERT 
_hTR 
__ pS3 
-- OAPDH 
Figure 1: hTERT and bTR expression in human colorcctal tissues delemllned by RT-PCR. 
Amplification of p53 and GAPDH were used to demonstrate the integrity of eDNA templates. Total 
RNA was treated with DNase I before eDNA s}1llhcsis. Results of telomerase activity. detemlined by 
the TRAP assay. are shonTI for each colorectal tissue. A size marker, 100 bp laddcr, was also shO\\TI in 
lane M. In the negative control no RNA was added in the RT~PCR reaction. 
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Table I ~ Correlation between telomel'ase activity and expression of telomerase 
genes in colorcctal tissues 
RNA expression! RNA expression / Number 
Telomerase positive Telomerase negative of cases 
hTERTmRNA 
adenocarcinoma 25/25 (100%) 0 25 
adenomaHG 9110 (90%) 0 10 
adenoma LG 4/4 (100%) 0116 20 
HonnaI mucosa 0 0/15 15 
hTRRNA 
adenocarcinoma 25/25 (100%) 0 25 
adenomaHG 10/10 (100%) 0 10 
adenomaLG 4/4 (100%) 2/16 (13%) 20 
nornlal mucosa 0 1/15 (6%) 15 
Correlation between telomerase activity and expression of telomerase subunits, 
hTERT and hTR, is statistically significant by chi~sqllare test. (P < O.OOOl)The peR 
assay for hTR was positive in all tissue samples when RNA was not treated with 
DNase prior to PCR. Fllrthennore, an amplified band of the expected size was 
observed when the RNA was not reverse~transcribed (Fig. 2). These findings indicate 
that part of the amplified product might have come from DNA contaminating the RNA 
preparations. To eliminate this DNA contamination, the samples were treated with 
DNase I. The DNase-treated samples were investigated by peR with and without prior 
reverse-transcription (RT), an amplified band of the expected size was never observed 
without RT (Fig. 2). By RT-PCR, hTR transcripts were present in all carcinomas, in 
all 10 adenomas with HG dysplasia, in 6 of 20 adenomas with LG dysplasia, and in 
only one out of 15 Homlal mucosa samples (Fig. 1). To test the possibility that DNase 
digestion might degrade RNA, undigested and digested RNA were subjected to 
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hTERT RT-PCR in these 70 colorectal tissues, and the same cases were found 
amplified, As shown in table 1, hTR specific transcripts were prescnt in all colorectal 
tissues with tclomcrase activity, but also in two adenomas with LO dysplasia and one 
nomlal colorectal mucosa sample without telomerase activity (P<O.OOOI by the chi-
square test), The nonnal mucosa which gave a positive hTR result was histologically 
fe-evaluated, The sample contained many lymphocytes, but it was also the case in four 
other nonnal mucosa samples without hTR RNA. 
RT-PCR with 
total RNA 
RT-PCR with 
DNA-free RNA 
peR 
Figure 2: Expression of hTR determined br HT-peR: innucnce of DNase treatment, Total RNA 
(without DNase treatment) or DNA-free RNA (with DNase treatment) samples were investigated with 
both PCR (when the RNA had not been Ieverse transcribed) and RT -PCR. Upper panel shows that hTR 
RNA expression was ubiquitouslr observed in cancerous and non-cancerous tissues, obviouslr due to 
the presence of genomic DNA in total RNA preparation (second panel). The third panel shows that hTR 
RNA is expressed at a high level in telomerasc-positive tissues and at a low level in few telomerase-
negative ones, Whereas no hTR product was obtained by PCR after DNase treatment (last panel). 
Results oftelomerase activity, detennined by the TRAP assay, are sho\\TI for each colorectaltissue. 
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DISCUSSION 
To dctemline whether a close correlation exists between telomerase activity 
and expression of tclomerase subunits, hTERT and hTR, during colorectal 
carcinogenesis, 70 colorectal tissues were investigated. For each sample, total RNA for 
detecting telomerase gene expression and protein for detecting telomerase activity 
were obtained from the same area of tissue samples with histological and tissue quality 
control. 
Telomerase activity coincided almost perfectly with expression of both 
tclomerase subunits, hTERT and hTR. hTERT was expressed in all except one 
telomcrasc·positive tissue sample, hut never in tc!omerase·negalive samples. A single 
discordant sample with telomcrase activity and hTR transcripts but without hTERT 
mRNA was found. This might be explained by altematively spliced hTERT 
transcripts, which might have been synthesised as observed in tissues during 
development (22,23), or by different rates of disintegration of the telomerase enzyme 
and the hTERT mRNA. As telomerase activity coincides almost perfectly with 
expression of the hTERT mRNA, this might be used as a marker for telomerase 
activity. 
In an ill vitro telomerase reconstituting cxperiment, it has been shown that hTR 
is an essential component of tclomerase (9). However, to what extent hTR exprcssion 
correlates with telomerase activation in human tissues is dcbated. Expression of hTR 
has been observed by RT-PCR in almost all the tissues analysed (7,8,10,14,15), 
whereas, by in situ hybridisation, hTR expression correlated well with telomerase 
activity (10-13). These contradictory results might be cxplained by a difference in 
sensitivity between RT-PCR and in situ hybridisation. If so, this implies that hTR 
might be expressed at least at a basal level in a wide variety of tissues. An alternative 
explanation might be an artefact of RT -PCR, i.e. amplification of genomic DNA 
sequences, RNA extracted from tissues is generally contaminated with a certain 
amount of genomic DNA. hTR DNA might be simultaneously amplified during hTR 
RNA amplification by RT-PCR, and thus lead to false-positive results. To tcst this 
hypothesis, we treated total RNA extracts with DNase to eliminate genomic DNA. 
With this additional step, hTR RNA was detected almost exclusively in telomerase-
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positive cases. Nevertheless, hTR RNA was also found by RT-PCR in 3 telomerase-
negative samples: two adenomas with only LG dysplasia and one normal colorectal 
mucosa. We conclude that previously reported hTR RNA transcripts as detemlined by 
RT-PCR in telomerase-negative samples arc most likely due to amplification of 
genomic hTR DNA and not to a ubiquitous low rate of expression of the telomerase 
RNA component. In our series, only 10% (3/31) of telomerase-negative colorectal 
tissues expressed hTR. These results were in accordance with a recent rcport where 
DNase digestion was performed before eDNA synthesis and hTR RNA was detected 
in only 15% of nomlal urine samples but in 83% of urine from patients with bladder 
cancer (24). 
In summary, our findings demonstrate that there is a very strong correlation 
betwecn tclomerase activity and the expression of hTERT mRNA and hTR RNA 
dctcnnined by RT -peR in colorectal carcinogenesis. hTR transcripts, however, occur 
also in some telomerase negative tissues, and our results arc in keeping with the 
concept that hTERT expression is a major regulator oftclomerase activity. 
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ABSTRACT 
Telomerase activity (TA) is detected in most human cancers but, with few 
exceptions, not in nanna! somatic cells. Little is known about TA in soft tissue tUlllors. 
We have examined a series of benign and malignant soft tissue tumors for telornerase 
activity using the telomerase rcpeat amplification protocol (TRAP) assay. Analysis of 
the expression of the human telomerase reverse transcriptase (hTERT) was also carried 
out, using RT -peR. TA was undetectable ill benign lesions (I5 of 15), low-grade 
sarcomas (6 of 6), and 50% (19 of 38) ofintermcdiate-/high-grade sarcomas. Although 
the presence afT A in soft tissue tumors is synonymous with malignancy, it is neither a 
reliable method in making the distinction between reactive/benign and malignant 
(especially low-grade) lesions nor a reliable marker of tumor aggressiveness, 
Leiomyosarcomas and storifonn/pleomorphic malignant fibrous histiocytomas rarely 
showed TA, irrespective of their grade. A strong correlation between hTERT mRNA 
expression and TA was observed, supporting the close relationship between both 
parameters, No significant relationship was observed between proliferative activity (as 
assessed by :MID-I immunolabeUing) and 'fA. We verified that the absence of 
telomerase expression was not due to the presence of te10merase inhibitors and 
therefore aitemative mechanism(s) for cell immortalization, yet to be dctcnnined, 
seem to be involved in the development and/or maintenance of some soft tissue 
sarcomas, 
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INTRODUCTION 
Telomerase is a complex enzyme containing both protein components and a 
RNA component. Its RNA subunit acts as a template for the synthesis of telomeric 
DNA, while a protein component, the human tclomerase reverse transcriptase 
(hTERTIhEST2), catalyzes this process to make up for the inability of cOllventional 
DNA polymerase to replicate completely the ends of linear DNA (1, 2). Telomerase 
activity is detected in most human cancers as well as in some precancerous lesions and 
benign tUlllors (3-5), It is usually not detected in 110nnal somatic cells except for 
uannaI human leukocytes (e.g. activated Band T lymphocytes), human gennline 
tissues (adult testes and ovaries, but not mature spennatozoa and oocytes), and 
proliferating stem cells (5). Recently, based on a large number of samples, Meeker et 
al. (3) summarized the current data on telomerase activity in human cancers using the 
peR-based TRAP assay. With the apparent exception of retinoblastoma which is often 
tclomerase negative (6), the prevalence of telomerase activity in human cancers 
appeared to vary between 82% and 100% (3). 
Owing to their rarity, ubiquitous location and significant morphologic 
diversity (more than ISO different histologic types described so far), soft tissue 
neoplasms are often a source of great difficulty in diagnostic pathology, especially 
when it comes to differentiating between benign and malignant lesions. Telomerase 
activity has been shown to be a potential useful diagnostic tool for the detection of 
cancer (5) as well as a potential prognostic marker for selected tumors (7-9). Apart 
from four sarcoma cases examined by Kim et al. in their study (1O), telomerase 
activity has so far not been systematically examined in soft tissue tumors. 
In the current study, we examined a series of benign and malignant soft tissue 
lesions for telomerase activity using the TRAP (Telomeric Repeat Amplification 
Protocol - TRAP) assay and for human telomerase reverse transcriptase (hTERT) 
mRNA expression. Since telomcrase activation and human telomerase RNA (hTR) 
expression generally correlate with growth rate (II-D), we also examined sarcomas 
for proliferative activity using Mib-I immunolabclling. We showed that reactive 
lesions, benign tumors, low-grade sarcomas and about 50% of intemlediate-/high-
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grade sarcomas were devoid of telomerase activity. When present, the latter correlated 
with hTERT expression but did not correlate with proliferative activity. We also 
showed that leiomyosarcomas and storifonn-plcomorphic malignant fibrous 
histiocytomas are predominantly telomerase negative neoplasms. 
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MATERIALS Al'lD METHODS 
Tissue Samples. From 54 patients, 59 frozen tissue samples, including 15 benign soft 
tissue lesions and 44 soft tissue sarcomas, were retrieved from the tumor banks of the 
University Institute of Pathology of Lausanne, Switzerland and from that of the 
Department of Pathology of the Bergonic Institute, Bordeaux, France (JMC). 
Histologic typing and subtyping was perfonned on fonnalin-fixed, paraffin-embedded 
sections stained with hematoxylin and eosin, using the histological classification of 
soft tissue tumors of the World Health Organization (14). Additional techniques, 
including immunohistochemistry and electron microscopy, were lIsed for diagnostic 
purposes if necessary. Histologic grade was established using the updated version of 
the French Federation of Cancer Centers grading system (15). 
All tissue specimens were serially sectioned. Of 10 sections, the first and the 
last were cut at 5 ~m and stained with hematoxylin and eosin for conventional 
microscopic examination, in order to assess tissue preservation and the relative amount 
of tumor tissue in the specimen available. Any specimen containing less than 30% 
tumor cells was excluded from the series. Intennediate sections were cut at 12 ~tm and 
put into two chilled 1.5 1111 Eppendorf tubes, using a tapered glass pipette, for 
extraction of protein and total Rt'\JA. Depending on the size of tissue samples, between 
1 and 5 tissue sections provided sufficient material for protein extraction in 30 ~l of 
CHAPS lysis buffer for detemlination of telomerase aclivity. For a sufficient amount 
of RNA, 5 to 10 sections were necessary. 
Total RNA was extracted and its quality assessed as previously described 
(16). Following extraction using Trizol (Life Technology) and ethanol precipitation in 
presence of I O~g glycogen, total RNA from soft tissue lesions was redissolved in 20Jti 
of RNase-free water. About 0.6-1.0 ~g oftola1 RNA was subjected to 1% agarose gel 
electrophoresis. Preservation of 28S and/or 18S ribosomal RNAs species (rRNAs) 
were used to assess RNA degradation. Samples in which 28S andlor 18S RNA was no 
longer detectable were not tested for tc!ol11crase activity. 
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TRAP assay. Telomerase activity was detennined using the TRAP assay with some 
modifications (17). SW480 colorectal carcinoma cells were used as a positive control 
in the PCR amplification. To this end, cell pellets (about I x 10' cells) were suspended 
in 400 ~tl of CHAPS lysis buffer. Frozen tissue sections (l to 5 sections) were 
homogenized with 30 111 of CHAPS lysis buffer. After incubation for 30 mill on ice, 
the lysate was centrifuged and the supernatant was inUllcdiately frozen at -80°C and 
stored until use. Protein concentration of the extract was measured by the BCA protein 
assay kit (pierce Chemical Corp., Rockford, Illinois, USA). 
In every case, the TRAP assay was perfomled using 3 different concentrations 
of the protein extract, 0.1, 0.5, and 1.5~lg respectiYely. The protein aliquot was 
incubated with 20 111M Tris-HCI (pH 8.3), 1.5 1l1~\'1 MgCI2, 63 mM KCl, 0.005% 
Tween-20, mM EGTA, 100 ~tM dNTPs, 50 ng of TS primer (5'-
AATCCGTCGAGCAGAGTT-3') in a themlOcycier for 30 min at 30°C for the 
generation oftelomeric repeats. After heating at 94°C for 2 min and cooling at 72°C, 1 
unit of Taq DNA polymerase, 50 ng of ACX return primer (5'-
GCGCGG[CTTACC]3CTAACC-3'), 50 ng of NT internal control primer (5'-
ATCGCTTCTCGGCCTTTT-3') and 0.01 amol of TSNT internal control (5'-
AATCCGTCGAGCAGAGTTAAAAGGCCGAGAAGCGAT-3'), were added to a 
total reaction yolume of25 ~d. Then, 30 PCR cycles (94°C for 30 s, 56°C for 45 sand 
72°C for 45 s) were perfonned. Five ~d of PCR product was electrophoresed on a 8% 
polyacrylamide nondenaturing gel. The gel was stained with SYBR Gold (Molecular 
Probes, Eugene, Oregon, USA) and visualized under UV light using a charge coupled 
deyice (CeD) camera. The TRAP assay included the amplification of an intemal 
control of 36 base pairs (bp); a false -negative result due to the presence of PCRlTaq 
DNA polymerase inhibitors was concluded when the 36-bp amplified product was not 
observed. 
Analysis of hTERT expression by RT -peR. Analysis of the expression of human 
telonterase reverse transcriptase (hTERT) was carried out by RT-PCR. eDNA was 
synthesized from 5-10 Jig of total RNA using random primers. To amplify the reverse-
transcribed eDNA, 2 ~t1 aliquots of cDNA wcre SUbjected to 40 PCR cycles (95°C for 
30 s, 65°C for 45 s and 72°C for 45 s) in 20 Jd volume containing lOx Taq buffer, 50 
ng of upstream primer 5 '-TTCCTGCACTGGCTGATGAGTGT-3 , and 50 ng of 
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downstream primer 5' -CGCTCGGCCCTCTTTTCTCTG- 3', 250 JIM dNTPs and 1 U 
Taq DNA polymerase (Boehringer Mannheim). The primers correspond respectively 
to portion 1686 to 1708 and 1994 to 2014 of the published hTERT mRNA sequence 
(l8). PCR products were analyzed on an 1.5% ofagarose gel. The size of the hTERT 
PCR amplified product was 329 bp. The quality of eDNA was controlled by PCR 
amplification of p53 and GAPDH (glyceraI-dehyde-3-phosphate dehydrogenase) 
transcripts. 
Detection of teiomerase inhibitors. Fourteen cases were examined for the potential 
presence of tclomerase inhibitors. These included 4 sarcomas [Cases 18, 19, 23, and 
24; Table I] with undetectable teiomerase activity despite hTERT mRNA expression 
and 10 lesions [Cases 16,21,22,33,42,44,49,51,54, and 58; Table I] which were 
hTERT and teiomerase negative. To this end, the TRAP assay was perfornled in 
parallel with cell extracts obtained from tumor tissue alone, hUllor tissue mixed with 5 
x 105 (5 JlI) SW480 colorectal cancer cells, and SW480 cells alone. When only the first 
cell extract gave a negative TRAP assay (with the 36bp internal control amplified), 
this was taken to indicate the absence of telomerase inhibitors in the tumor tissue 
extract. 
Immullohistochemistry. For all sarcoma cases, additional frozen sections were cut 
and stained with the Mib-l antibody, recognizing the cell cycle-associated antigen Ki-
67 (Immunotech SA, Marseille, France, diluted lila). Proliferation index was defined 
(after semiquantitative assessment of the staining) as low when less than 5%, moderate 
when 5 to 15%. and high when more than 15% of the nuclei were stained. 
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RESULTS 
Fifteen reactivclbenign lesions and 44 soft tissue sarcomas (SIS) were 
included in our study. Of the latter, 6 tumors corresponded to local sarcoma 
recurrences [Cases 16, 18, 19,24,25, and 54] and 9 to sarcoma metastases located in 
the lungs [Cases 33, 34, 57, 58, and 59J and soft tisslies [Cases 28, 30, 47, and 55J (see 
Table 1). From one patient, tissue samples from the primary tumor [Case 23] as well 
as from a locally recurrent lesion [Case 24] were available for examination. From 
another patient, the primary tumor [case 26] and two thoracic wall metastases [cases 
30 and 471 and from a third patient a local recurrence [case 54J and a lung metastasis 
[case 33J could be analyzed. Of one patient we analyzed two lung metastases [Cases 
57 and 58]. Two patients [Cases 23 and 53J received neoadjuvant chemotherapy prior 
to tumor sampling. The distribution according to histologic types and subtypes and 
histologic grade is shown in Table 1. 
Telomerase activity was undetectable in benign soft tissue lesions (including 
14 tumors and onc myositis ossificans) whereas it was observed in 19 of 44 (43%) soft 
tissue sarcomas (STS). None of low-grade (grade 1), 9 of 16 (56%) intemlediate-grade 
(grade 2), and 10 of22 (45%) high-grade (grade 3) STS showed teiomerase activity 
(Table 1; Fig. 1.). There was no correlation between histologic grade and telomerase 
activity using the Chi-square test (p mille = 0.06). Only one [Case 52] out of 10 
leiomyosarcomas and one [Case 59] out of 7 storifonll/pleomorphic malignant fibrous 
histiocytomas expressed telomerasc activity, irrespective of tumor grade. Most (5 of6) 
locally recurring sarcomas failed to display tclomerase activity. Five sarcoma 
metastases out of 9 (56%) were telomerase positive. Two sarcoma patients showed 
concordant telomerase activity status between the primary tumor and the 
corresponding recurrence [Cases 23 and 24] and between the primary tumor and the 
corresponding metastases [Cases 26, 30, 47J. 
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Fig. J. Telomerase activity using TRAP assay in benign and malignant soft tissue tumors. Selected 
exemples ofgradc 3, grade 2, grade 1, and benign soft tissue tumors include an angiosarcoma (Case 43), 
a round cell liposarcoma (Case 29), an unclassificd spindle cell sarcoma (Case 21), and an hemangioma 
(Case 5). The TRAP assay was performed using 3 diflerent concentrations of the protein extract, 0.1, 
0.5, and I.S ~tg respectivcly. L1Ilc I : pGEM DNA size markers (Promega, Madison, WI, USA). Lane 
2: Colorcctal eancer cell lines SW480 as a positive control. 
hTERT mRNA was detected in 19 (44%) of43 STS including 15 of 18 (83%; 
Case 26 not available) telomerase-positive and 4 of 26 (15%) telomerase-ncgative 
cases. A strong correlation between hTERT mRNA expression and tclomerase activity 
was demonstrated using the Chi-square test (p value < 0.0001). None of the benign 
lesions expressed hTERT mRNA. In three cases (Cases 34. 38 and 41). marked 
telomerase activity was observed in the absence of detectable hTERT mRNA. A lack 
of expression of both enzyme activity and hTERT mRNA was observed in 21 of 43 
sarcomas (49%; case 26 not available), recurrences and metastases included. Ten of 
these cases [Cases 16,21.22.33,42,44,49,51.54. and 58] were examined for the 
presence oftelomerase inhibitors and all proved to be negative (Fig. 2.). In none of the 
4 telomerase-negative, hTERT-positive sarcomas [Cases 18, 19, 23. and 24] was the 
lack oftelomerase activity due to the presence oftelomerase inhibitors. 
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Fig. 2. Defection or tdomerase Inhibitors. Protein extracts from a leiomyosarcoma (Ll>.lS) (Case 51) 
were successively examined prior to and after complementation with extracts from SW480 coloreclal 
cancer cells. The laller showed telomerase activity and was used as a control (lane 2). Tclomemsc 
activity was not detected in the protein extract from the leiomyosarcoma when taken in isolation (lanes 
3, 4 and 5). After complementation with SW480. telomerase activity was restored (lanes 6, 7 and 8) 
indicating that the lack of telomerase expression in the leiomyosarcoma was not due to the presence of 
telomerase inhibitors. The amplified 36bp internal control acknowledges the absence of PCRlfaq DNA 
polymerase inhibitors. The TRAP assay was performed using 3 different concentrations of the protein 
extract, 0.1, 0.5, and 1.5 ,Ig respectively. Lane I : pOEM DNA size markers (Promega, Madison, WI, 
USA). Lane 2 : ColoTl.~ctal cancer cell lines SW480 as a positive control. 
The· MIB-l (Ki·67) labelling index was assessed in 41 STS. Low and 
intennediate Mib-l labelling indices were detected in 34 STS (83%). High labelling 
indices (> 15%) were observed in the high·grade (03) tumor category only. Local 
recurrences and sarcoma metastases showed Mib-l labelling index equal or below 
15% (see Table 1.). There was no relationship between Mib-l indices and telomemse 
activity (p value = 0.33). 
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Table 1. Telomerase and hTERT mRNA expression in benign and malignant 
soft tissue tumors 
% Mib-l-
Case Histology hTERT positive 
no. expression TA nuclei 
Benign lesions 
Lipoma ND 
2 Lipoma ND 
3 Intramuscular lipoma ND 
4 Intramuscular lipoma ND 
5 Intramuscular hemangioma ND 
6 Intramuscular hemangioma ND 
7 Hemangiomatosis ND 
8 Desmoid tumor ND 
9 Desmoid tumor ND 
10 Desmoid tumor ND 
11 Desmoid tumor ND 
12 Desmoid tumor ND 
13 Cellular schwannoma ND 
14 Ossifying myositis ND 
15 Localized giant cell tumor of tendon sheath ND 
Low-grade sarcomas (Grade 1) 
16 Well-diff_ liposarcoma (R) NA 
17 Myxoid liposarcoma 1% 
18 Myxoid liposarcoma (R) 1% 
19 MFH, storiform-pleomorphic type (R) 10% 
20 Leiomyosarcoma NA 
21 Unclassified spindle cell sarcoma / fibrosarcoma 1% 
Intermediate-grade sarcomas (Grade 2) 
22 I\IFH, storiform-pleomorphic type 5% 
23 MFH, storiform-pleomorphic type (post CT***) + 1% 
24 MFH, storifoffil-pleomorphic type (R) + 1% 
25 MFH, giant cell type (R) + +++ 5% 
26 Myxoid liposarcoma NA + 10% 
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27 J\'fyxoidlround cell liposarcoma + ++ 2% 
28 Myxoid + round cell liposarcoma (M) + +++ 5% 
29 Round cell liposarcoma + ++ 1% 
30 Round cell liposarcoma (/1.1) + +++ 1% 
31 Dedifferentiated liposarcoma 1% 
32 Leiomyosarcoma 5% 
33 Leiomyosarcoma (M) 1% 
34 MPNST(M) +++ 1% 
35 l\.fyxoid chondros3n::oma + + 1% 
36 Unclassified spindle cell sarcoma I fibrosarcoma + + 15% 
37 Unclassified spindle cell sarcoma I fibrosarcoma 10% 
High-grade sarcoma (Grade 3) 
38 DSRcr oftbe abdomen +++ 50% 
39 MPNST + ++ 25% 
40 MPNSP** + + 70% 
41 Embryonal rhabdomyosarcoma +++ 35% 
42 Alveolar rhabdomyosarcoma NA 
43 Angiosarcoma + tt+ 70% 
44 MFH, myxoid type 15% 
45 Pleomorphic liposarcoma 5% 
46 Pleomorphic liposarcoma 40% 
47 Round cell liposarcoma (M) + ++ 10% 
48 Synovial sarcoma (monophasic type) + +++ 15% 
49 Leiomyosarcoma 1% 
50 Leiomyosarcoma 15% 
51 Leiomyosarcoma 25% 
52 Leiomyosarcoma ++ 15% 
53 Leiomyosarcoma (post CPU) 5% 
54 Leiomyosarcoma (R) 1% 
55 Leiomyosarcoma (M) 15% 
56 Unclassified spindle cell sarcoma I fibrosarcoma +++ 2% 
57 MFH, storiform-pleomorpllic type (M) 10% 
58 MFH, storifoml-pleomorphic type (M) 10% 
59 MFH, storifonn-pleonlOrphic type (M) + + 1% 
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* - no activity; + low activity; ++ moderate activity; +++ marked activity 
** % positive nuclei 
*** Tumor grade assessed on incisional biopsy, prior to neoadjl1\'ant chemotherapy. 
MPNST: malignant peripheral nerve sheath tumor; MFH: malignant fibrous histiocytoma; 
Well·diff. liposarcoma: well-differentiated liposarcoma; DSRCf: desmoplastic small round cell 
tumor 
(R): local recurrence; (M): metastasis 
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DISCUSSION 
Telomerase activity has been shown to be activated in the majority of 
epithelial cancers (5) and may provide a useful diagnostic or prognostic indicator in 
epithelial but also glial neoplasms (7. 9, II, 19). Little is known about telomerasc 
activity and its potential diagnostic and prognostic implications in soft tissue lesions. 
The purpose of the cument study was to clarify this issue. 
Telomerase activity is undetectable in all benign lesions but also in all low-
grade sarcomas as well as in approximately 50% of the intemlcdiate-/high-grade 
sarcomas. This indicates that in all likelyhood a leiolllcrase-positive tumor is a 
sarcoma, but when telomerase is negative, it has no value as a parameter for predicting 
behavior. 
Before concluding, one must nile out the possibility of false-negative results. 
The TRAP assay used for the detection of telomerase activity is subject to limitations 
(16, 17,20) and requires positive and negative controls. In the current study, every 
frozen tissue specimen was histologically controlled before submission to be sure that 
it was qualitatively and quantitatively representative of the tumor. Tissue quality is of 
vital importance for the success of the teiomerase detection assay. Recently, we 
developed a quality test in which the preservation of28S andlor ISS ribosomal RNAs 
specics is used to assess total RNA degradation (16). Of the 99 mesenchymal lesions 
originally selected for this study, 59 only met the quality lest requirements and were 
subsequently retained for analysis. A second reason for false-negative results might be 
the presence of Taq DNA polymerase inhibitors or telomerase inhibitors as illustrated 
in Hodgkin's disease. Until recently, Hodgkin's disease was thought to be a 
predominantly teiomerase negative Icsion (21). However, a rccent study (22) showed 
that this apparent lack of teiomerase activity was due to the presence of telomerase 
inhibitors, more specifically eosinophil-associated ribonucleases. The potential 
presence of inhibitors was carefully examined in the current study. To detect Taq DNA 
polymerase inhibitors, we used the TRAP assay described by Kim et al. (17) which 
includes the amplification of an intemal control of 36 base-pairs (bp) in each assay, 
and a false-negative result is concluded when the 36-bp amplified product is not 
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observed. To detect telomerase inhibitors, protein extracts from each specimen were 
examined before and after spiking with telomerase-positive SW480 colorectal cancer 
cells. Absence of detectable telomerase activity in the spiked extract was taken to 
indicate the presence of lelomerase inhibitors. No inhibitors could be detected using 
any of these methods. 
A strong correlation between hTERT mRNA expression and telomerase 
activity was observed in 36 out of 43 (84%) STS (p<O.OOOI), hence supporting the 
close relationship between both parameters and the crucial role of the hTERT gene 
upreglllation in telomerase activation (18, 23-26). Four hTERT-positive STS failed to 
express detectable enzyme activity and we showed that this was not due to the 
presence of telomerase/PCR inhibitors. The presence of alternately spliced hTERT 
transcripts deleted in critical regions of the reverse transcriptase (25, 26), abnomlalities 
in the RNA template component of tciomcrase, or unbalanccd levels of expression 
and/or posttranscriptionnai modifications of the dificrcnt tclomcrasc subunits (hTR, 
TLPl, and hTERT) (23, 26) could account for enzyme inactivity and, thus, explain 
those discrepancies. Telomerasc activity was observed in the absence of detectable 
hTERT mRNA in 3 cases. In the latter situation, an increased degradation rate of the 
hTERT mRNA compared to that of the enzymc may explain this type of discordance. 
A rccurrent and crucial problem in diagnostic pathology is to differentiate tme 
sarcomas from clinically benign but morphologically malignant-looking soft tissue 
lesions. Nodular faseiitis and myositis ossificans are prototypical exemples of such 
lesions. All benign lesions of our series (including a case of myositis ossificans) were 
negative for telomerase. Since 57% of sarcomas wcre also telomerase-negative lesions 
(including malignant fibrous histiocytomas and leiomyosarcomas), we therefore 
conclude that te!omerase activity cannot be used to distinguish a benign lesion from a 
malignant one. This observation is of particular importance for the pathologist since 
malignant fibrous histiocytoma and leiomyosarcoma are those sarcomas which are 
most likely to be confused with pseudosarcomatolls lesions. Along the same line, 
telomerase activity calIDot be used to separate a well-differentiated fibrosarcoma from 
a desmoid tumor or a well-differentiated "lipoma-like" liposarcoma from a 
conventional lipoma, all four lesions being telomerase negative. 
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In about 50% of the intemlediate- and high-grade STS, telomerase activity 
was undetectable. In addition, several locally recurring tumors and metastases did not 
express telomerase activity. TIlls indicates that telomerase activity is not a reliable 
marker of aggressiveness in STS and cannot be llsed as a prognostic indicator in this 
tumor category, contrasting with what has been reported for epithelial neoplasms (9, 
19), neuroblastoma (8), meningioma (7) and several other tumor types (5). Although 
our series included a limited number of cases pcr histologic category, which precludes 
definitive conclusions, telomerase activation might be histology related in being 
predominantly negative in leiomyosarcomas and malignant fibrous histiocytomas. 
Neither telomerase activity nor hTERT mRNA was found in 21 of 43 (49%) 
STS, including two recurrences and four metastases. This suggests that telomerase 
activity is not an essential prerequisite for sarcoma development nor for its metastatic 
dissemination. Similar observations were made for transplantable osteosarcomas (27) 
as well as in renal cell carcinoma (28) and retinoblastoma (6). To explain the absence 
of telomerase activity in some tumors despite optimal tissue preservation and absence 
of teiomerase inhibitors, the existence of an altemative telomerase-independent 
mechanism for cell immortality via telomere lengthening has been suggested (10, 29, 
30). Although such a mechanism might be operative in some sarcomas and sarcoma 
cell lines (29, 30), it is unlikely to be universal. Indeed, a recent study (31) showed that 
about half of STS have short teloillcres whereas in only 17% of the tumors examined 
the chromosomes had elongated telomere repeats. In addition, this study also showed 
differences in telomere length pattems between primary tumors and recurrences. Based 
on the latter findings, telomere lengthening, whether it occurs through telomerase 
activation or not, is unlikely to playa dominant role in sarcoma development and 
maintenance. Additional studies focusing on the relationship between telomere length 
and telomerase activity in STS are needed to clarifY this issue. Another explanation 
which would account for the lack oftelomerasc activity in a significant number of STS 
is the fact that telomerase expression might be a field andlor a time dependent 
phenomenon. Indeed, intratumoral variations in teloll1erase expression have recently 
becn documented in high grade astrocytomas (12) ;md it is conceivable that such a 
phenomenon occurs also in STS. Telomerase activity and human telomerase RNA 
(hTR) expression generally correlate with growth rate (11-13) and one might suppose 
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that the lack of telomerase activity in some STS is associated with low proliferative 
activity. Indeed, most of our telomerase·negativc STS showed a low proliferation rate 
as assessed by Mib-l staining suggesting a relationship between both parameters. 
However, this is hampered by the fact that 76.5% of telomerase·positive STS showed 
also low labelling indices (i.e. Mib-l positivc nuclei ratio equal or lcss than 15%), 
hence precluding any conclusions. 
In conclusion, we showed that telomerase activity and hTERT mRNA are not 
expressed in benign mesenchymal lesions. In soft tissue sarcomas, telomerase activity 
is restricted to a subset of intemlediate- and high-grade sarcomas, might be histology 
dependent and, as yet, cannot be used as a diagnostic or prognostic tool. 
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ABSTRACT 
Purpose: Tciomcrase activity is absent in most somatic cells, but it has been 
found to be reactivated in a majority of cancers. OUf principal goal was to test whether 
the presence of te10merase activity concurred with positive cytology in detecting 
cancer cells in effusion diagnosis. 
Patients alld Afethods: Telomcric repeat amplification protocol (TRAP) assay 
and cytological examination were pcrfonned in a blinded fashion on 91 pleural, 
peritoneal, and pericardial unsclccted fluids from 86 patients, without any change of 
routine cytologic sampling. In order to reduce the chance of a false-negative TRAP 
assay, the integrity ofrRNA in the effusion cells was verified in each case. 
Results: According to clinical context, 42% (38/91) of samples can be 
considered as malignant effusions by either cytologic examination of TRAP assay, 
whereas only 30% (27/91) were found malignant by cytology alone. Concordance 
between the tclolllerase assay and cytologic examination was observed in only 63 
(69%) cases. Of the 28 non-concordant cases, 8 had a positive cytology without 
detectable tclomerase activity. In 6 of these cases rRt'JA was almost completely 
degraded, and thus absence of tclomerase activity might be due to bad cell 
preservation. Negative cytology in the presence of teiomerase activity was found in 17 
cases. Eleven of them were associated with a malignancy and thus a diagnosis of 
malignant efttlsion should be strongly suspected. For the 6 patients with telomerase 
activity in effusion and no preexisting cancer, a longer follow-up will be necessary. 
Conclusion: These results suggest that teiomcrase activity is morc often found 
in effusions than cytologically malignant cells. To some extent this indicates a higher 
sensitivity of telomerase assay for the detection of malignant cells than cytology, and 
thus the TRAP assay could become, in certain conditions, a useful adjunct in routine 
cytologic examination. 
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INTRODUCTION 
Identifying tumor cells in body cavity effusions is a well~known diagnostic 
problem. Cytological examination is the most specific method for the diagnosis of a 
malignant effusion, Although the specificity of the lest is vcry high, according to most 
studies the overall sensitivity ranges between 70% and 95% (I ~3). Low sensitivity may 
be caused by presence of few malignant cells in the cell sample and by the limitations 
of the morphological approach: it can be difficult to differentiate between malignant 
and reactive cells. To improve the sensitivity of cytological examination, various 
approaches have been proposed, including immunocytochemistry (4,5), chromosome 
analysis (6), tissue culture techniques (7), DNA flow (8,9) or image cytometry (10), 
and cell image combincd with immunocytochemistry (11). However, all these special 
techniques have a limited impact in routine cytological diagnosis. New approaches 
have to be developed in ordcr to improve the sensitivity of cytological diagnosis in 
effusions, 
The telomere-telomerase hypothesis of cell aging has rapidly become a focus 
of intensive research in the field of carcinogcnesis. The hypothesis is based on the 
observation that telomerase activity is expressed in embryonic cells, in adult gennlille 
cells (12,13), and in most human tumors (12,14), but is undetectable in nonnal somatic 
tissues except for proliferative cells of renewable tissues including haemopoietic stem 
cells (15,16), basal cells of the cpidennis (17) and intestinal crypt cells (18), Human 
telomeres, which are eomposcd of many kilobases ofTTAGGG repeats and associated 
proteins, protect and stabilize chromosome ends during DNA replication (19), In 
nonnal somatic cells telomeric DNA is reduced during each cell division, In contrast, 
tumor cells show a stability of average telomere length with cell division, suggesting 
that telomere stability may be required for cclls to escape from replicative senescence, 
allowing them to proliferate indefinitely. Telomere lcngth stability appears to be the 
consequence of telomerase activation. Telomerase, a ribonuclcoprotein complex, is a 
specialized reverse transcriptase that synthesizcs telolllcric DNA sequences and thus 
restores telomere length (20,21). Telolllcrase activity has been detected in a great 
majority of human cancer tisslies and cancer cell lines tested to date (22), and thus it 
may be an excellent marker to distinguish malignant cells from non11a1 somatic cells, 
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Telomerase activity is generally detected by the telomeric repeat amplification 
protocol (TRAP) assay (12), which is a sensitive, reliable and reproducible test. Thus, 
testing for telomerase by the TRAP assay in body cavity fluids might be a approach to 
detemline the presence of malignancy. 
The aim of this study, therefore was to detenlline to what extent telomerase 
activity as measured by the TRAP assay could be an additional approach in routine 
cytological diagnosis to differentiate benign frolllll1alignant effusions. 
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PATIENTS AND METHODS 
Patients and Cytological Samples. From November 1997 to April 1998, 91 
unselectcd effusion samples were collected from 86 patients, submitted for cytological 
examination at the Department of Pathology of Lausanne. These included 49 men and 
37 women aged 3 to 90 years (median: 63.9 years). The cytological material consisted 
of 59 pleural, 29 ascitic and 3 pericardial fluids. Tclomcrase assay and cytological 
examination were perfonncd independently in a blinded IlHUmer. There was no 
exchange ofinfomlation until the end of the study. 
The fluid samples were used first for standard cytologic examination, including 
Romanowsky method and Papanicolaou stain. At the end of this examination the rest 
of the material was used for the telolllcnlsc assay. Cclls in pleural, peritoneal or 
pericardial effusions wcre collected by ccntrifugation at 2'000 rpm for to min at 4°C. 
To avoid contamination with red blood cells that could potcntially intcrfere with PCR, 
cells were washed 2 to 4 times with ice~cold hypotonic solution (50 111M KCI) and then 
kept frozen at ~80°C. 
Control of Tissue Quality. Cell integrity was measured using RNA integrity as a 
marker (23), Total RNA was extracted from I 0-20 ~II of frozen cells using Trizol (Life 
Technology), and after ethanol precipitation in presence of 1 O~lg glycogen, the pellet 
was redissolved in 20 ml of RNase-free water. About 0.5 mg of total RNA was 
subjected to 1 % agarose gel electrophoresis. If 28S and/or 18S ribosomal RNA bands 
appeared on the agarose gel, rRNA was at least partially intact. If no 28S and 18S 
rRNA bands presented, we concluded that rRNA was highly degraded, 
TRAP assay. For tumor cell lines, around 10& cells were Iyzed with 400 Illl of CHAPS 
lysis buffer. For cytological materials, I 0~20 1111 of frozen cells were lyzed with 100 Illi 
CHAPS lysis buffer. After incubation for 30 min on ice, the lysate was centrifuged and 
the supcmatant was immediately slored at -80°C. Protein concentration of the extract 
was measured by the BCA protein assay kit (Pierce Chemical Corp., Rockford, 
Illinois, USA). 
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Telomerase activity was dctemlined using the TRAP assay, according to the 
method reported by Kim and Wu (24), with some modifications. An aliquot of 0.5 mg 
of protein was incubated with 20 mM Tris-HC! (pH 8.3), 1.5 mM MgC12, 63 mM KCI, 
0.005% Tween-20, 1 mM EGTA, 125 ~lM dNTPs, 50 ng of TS primer (5'· 
AATCCGTCGAGCAGAGTT·3') in a themlOcycier for 30 min at 30°C for generation 
of telomeric repeals. After heating at 94°C for 2 min and cooling at noc, 1 unit of 
Taq DNA polymerase, 50 ng of ACX rehlnl primer (5'-
GCGCGG[CITACC]3CTAACC-3'), 50 ng of NT internal control primer (5'· 
ATCGCTTCTCGGCCTTTT-3') and 0.01 amol of TSNT internal control (5'-
AATCCGTCGAGCAGAGTTAAAAGGCCGAGAAGCGAT-3'), were added to a 
total reaction volume of 25 ml. Then 30 PCR cycles (94°C for 30 s, 56°C for 45 sand 
72°C for 45 s) were perfomled. Five Illi of the PCR products were electrophoresed on 
a 8% polyacrylamide nondenaturing gels. The gel was stained with SYBR Gold 
(Molecular Probes, Eugene OR, USA) and visualized under UV light using a CCD 
camera. 
Telomerase activity was also detennined using a modified sensitive TRAP 
assay. Generation of telomeric repeats was perfonned as above but with 2.5 J.lg of 
protein. After extraction with phenol I chlorofonn, the DNA was precipitated with 
ethanol and air-dried. A 30 ~ll PCR mixture containing 10 mM Tris (pH 8.8), 50 mM 
KCI, 1.5 mM MgCI2, 250 11M dNTPs, 100 ng of TS primer, 100 ng of ACX primer, 
100 ng of NT intemal control, 0.02 al110l of TSNT inlemal control and 1 unit of Taq 
DNA polymerase, was added to the extracted DNA. Then 30 PCR cycles were 
perfonned as above. 
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RESULTS 
Quality contl'ol of cytological materials. 
For reliable TRAP assay results optimal preservation of RNA in the effusion 
cells under investigation is essential (23). We tested tlus by measuring integrity of 
ribosomal RNAs (rRNA). Only 53 of the 91 (58%) cytology samples had intact or 
only partially degraded rRNA; in the other 38 cases rRNA was highly degraded (Table 
I and Figure I). The proportion of pleural and ascitic fluids with adequate rRNA 
preservation were very similar, 58 and 62% respectively. We subsequently examined 
the stability of rRNA in effusion cells left at 4°C, for prolonged periods of time. No 
systematic difference was observed between material after a short versus a long 
interval (Table I). 
Table 1: Stability of biological material in pleural, ascitic and pericardial fluids 
and relation to telomerase activity 
Total Pleural Peritoneal Pericardial Sampling Sampling TA+ TA-
<I day >1 day 
Good RNA 53 34 18 44 9 28 25 
quality (58%) (58%) (62%) (33%%) (59%) (56%) (53%) (47%) 
Bad RNA 38 25 II 2 31 7 8 30 
quality (42%) (42%) (38%) (67%) (41%) (44%) (21%) (79%) 
Total cases 91 59 29 3 75 16 36 65 
(65%) (32%) (3%) (82%) (18%) (40%) (60%) 
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RNA quality +++ ++ 
2 J 4 5 6 
+ 
7 8 9 10 
28S 
18S 
Figure 1: RNA qualily in cytological effusions. Total RNA extracted from effusions (lanes 3-10) was 
subjccted to 1% agarose gel e1cctrophroresis. Lanes 2 to 10 contained about 0.5 ~Ig of total RNA. Total 
RNA extract from the human colorcctal carcinoma cell line SW480 was used as a positive control (lane 
2), A size marker, the 100 bp DNA ladder (Life Technologies), was also sho\m in lane l. 28S and 18S 
rRNA species were indicated by arrows. 
Telomerase Activity in Body Cavity Fluids. 
Telomerase activity was measured by both the standard TRAP assay described 
by Kim and Wu (24) and our modified sensitive TRAP assay (Figure 2). To obtain a 
higher sensitivity of the standard TRAP assay two approaches were tested. Increasing 
the number of peR cycles led to a large number of false-positive results, probably due 
to artifacts in the reaction and the design of the peR primers (data not shown). The 
assay was also perfonned with an increased amount of protein cell extract. This led to 
a strong inhibition of the peR reaction. We solved this problem by introducing a 
phenol extraction and an ethanol precipitation step after the extension of the TS primer 
by the telomerase enzyme contained in the extracted protein sample. This permitted the 
use of larger amollnts of protein cell extract without inhibition of the peR reaction 
during the amplification step. Using this technique, we detected tclomerase activity in 
36 of 91 (40%) effusion samples. As expected, telomcrase activity was more often 
(p==0.002) observed in effusions with relatively well preserved rRNA (28/53 cases, 
54%) than in those with highly degraded rRNA (8/38 cases, 21 %)(Table I). 
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Intensity of 
TRAP assay 
Protein Wg) 
+ ++ +++ 
M 0.5 0.5 0.5 2.5 0.5 2.5 0.5 2.5 0.5 2.5 
2 3 4 6 7 8 9 10 II 
Telomerase product 
Internal control 
36bp 
Figure 2: Telomerase activity in crto1ogical effusions. From each effusion sample, telomerase assays 
were performed by the standard and by our modified sensitive TRAP assay using exlmcts containing 
respectively 0.5 and 2.5 Ilg ofproldn (lanes 4-11). The extract of the human colorectal carcinoma cell 
line SW480 was uscd as a positive control (lane 2). In negative control, no protein was added (lane 3). 
TRAP peR products were indicated by a vertical line. The 36-bp internal positive control band ,vas 
sccn in e,'cry lane (indicated by an arrow), and it was used to identify non-infornlalive specimens due to 
inhibitors ofTaq polymerase. A size marker, pGEM DNA markcr(Promcga), was also shown in lanel. 
Cytological Diagnostic and Telomerase Activity in Body Cavity Fluids, 
The TRAP assay and cytological examination were perfomled in a blinded 
fashion on the effusion samples. All cases positive by the TRAP assay but were 
interpreted as negative by cytological examination were carefully rescrcened by an 
expcricnced cytopathologist (R. R). According to the cytological diagnosis achieved, 
effusions were classified into malignant (27 cases) and non-malignant (64 cases). In 
only 66 of 91 cases (73%) concordance between cytological examination and 
telomerase assay was observed; in 19 of 27 cases (70%) both were positive whereas 
47 of 64 cases (73%) both were negative. The 28 (31%) non-concordant cases 
concerned pleural effusions (20 cases), ascitic (7 cases) or pericardial fluids (J case). 
Of the 27 cytologically malignant cases 8 (30%) were telomerase negative by 
the TRAP assay. In 6 cases poor rRNA ql,lality was observed; false-negative 
telomerase activity in these samples may have been due to poor cell preservation 
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telomerase activity in these samples may have been due to poor cell preservation 
(Table 2, samples I to 6). The twb other cases showed accurate malignant cytological 
diagnosis and the extracted rRNA was largely intact (Table 2, samples 7 and 8), The 
clinical evolution confimled the cytological diagnosis and thus the TRAP assay failed 
to detect these 2 cases, 
Of tile 64 1l00Hnaiignant effusions, 20 (31 %) of them were found to be positive 
by the TRAP assay. Three cases were highly suspect by cytological examination, and 
tumor were finally identified by immunocytochemistry (Table 2, samples 9 to II). In, 
17 cytologically benign effusions telomerasc activity was found. In 11 of these cases 
there was a strong clinical suspicion of malignant eft1lsion (Table 2, samples 12 to 22), 
In 8 cases, the patient had an advanced malignant tUlllor proved histologically, which 
indicates that the sample assayed by telomerase very likely contained malignant cells 
(Table 2, samples 12 to 19). In 3 cases, curative treatment of a malignant tumor had 
been perfonned a certain time before the effilsion developed, The presence of 
telomerase activity in the effusion might conccivably indicate re-appearance of 
malignant cells, even though cytological examination failed to identify them. In 6 
effusions, a positive TRAP assay occurred in spite of a negative cytological 
examination, and without any suspicion of a malignancy (Table 2, samples 23 to 28). 
In our series, sevcral consecutive effusions were obtained from 4 patients. In 
two patients, both the cytologic examination and leiomcrase activity of effusions 
yielded a negative result. In the two others, the last obtained effusion gave a positive 
result for both techniqucs. Yet analysis of thc previolls effusions had shown positive 
results for the TRAP assay, but wcre negative for the cytologic examination. 
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Table 2: Discordant cases between cytological diagnosis and te!omerase assay 
Sample fluid Innarrurution RNA C}tologic l't\ Follow-up Conclusion 
quality 
" 
diagnosis 
pleural m , adenocarcinoma 
pleUlal >H , epidermoid carcinoma 6 false-
nfgatiw 
pleural + ll~eH lymphDma telamu<lle 
coses 
pericardial breast carcinoma duela 
peritoneal T -l:elll}lIlphoma b"d 
l/t(Jterial 
6 peritoneal 
-
+ ovarian cardnoma 
pleural ++ + + epiderrooid cm:inoma 2 Inte 
false-
negali\'(> 
""ritonea! >H ++ adenocarcinoma Idamerase 
(ases 
pleural >H H adenocarcinoma J false 
negati..e 
10 pleural + .. , ++ lung carxcinoma byC)talagy 
11 p;:ritoneal .. .. , ++ breast carcinoma but + 
immllna· 
12 perit(Jneal m m ++ breast cardnoma 
13 peritoneal + ++ hepatocarcinoma 
14 pleural 
-
+++ pancreatic carcinom:l 81nte 
15 pleural ++H liposarCDma false-
nega/i..e 
16 pleural +++ ++ adenocarcinoma bycyl%gy 
17 pleural 
-
lung carcinoma 
18 peritoneal , lhercarxcinoma 
19 pleural +++ +++ ++ adenocarcinoma 
20 pleural ,++ ++ prostate adenocarcinoma J prJlential 
21 pleur.!l + colon adenocarcinom:l false-
nega/i) ... 
22 pleural >H , cpidcrrooid carcinoma bycylO!ogy 
2l pleural +++ +++ , 
24 pleural +++ + H lupus 6 pOlenlial 
25 pleural +++ nb fractures false-
pasilil'e 
26 pleural , ++ rib fracture Ie!amume 
(mrs 
2J pleural 
-
++ , post infection 
28 pleural 
-
BOOP 
+immumo: positivity by immunohistochemistry 
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DISCUSSION 
Although analysis in c)1ology is presently considered the "gold standard", Illis 
approach has its limitations (I). Few pathological cells or pathological cells with 
relatively itmoccnt morphology might escape attention. An important goal in the 
development of cytology would be the validation of new approaches that might 
efficiently supplement the conventional cytologic examination. Telomerase is 
expressed in almost all tumors and never in mature Honnal cells. Conceivably, the 
detection of teiomcrase activity could be a helpful tool to differentiate benign from 
malignant effusions. The results of our study indicate that the detection of teiolllcrase 
activity by the TRAP assay might potentially constitute a useful tool for detecting 
cancer cells in effusions. Indeed, combining the two techniques of cytological 
evaluation and detection oftelomerase activity, we were able to identify 42% (38/91) 
of effusions with a strong clinical suspicion of malignancy, whereas only 30% (27/91) 
of samples where found to be malignant by a unique cytological analysis. 
Of 64 cytologically nonmalignant effusions, 17 were positive by the TRAP 
assay. In a majority of these cases (11117, 65%), there was a strong clinical suspicion 
of malignancy, and thus telomerase detection using the TRAP assay was well 
correlated with the clinical status of the patients. Detection of cancer cells in effusions 
cytology may be influenced by the concentration and the morphology of cancer cells. 
The high sensitivity of the TRAP assay can ensure the detection of trace amounts of 
tumor cells in the presence of large excess of inflammatory or benign cells. In 
addition, some hnllors do not show noticeable nuclear atypias and might therefore be 
interpreted as Honnal cells. These phenomena may lead to false-negative cytological 
diagnoses. However, this limitation does not affect the TRAP assay because this assay 
is independent of the morphology of the tumor cells. 
For patients with telomerase positive effusions with presumably no preexisting 
cancer, additional studies are needed to understand better the factors associated with 
potential false~positive results. The role of large number of inflammatory cells in false-
positive results has also to be considered (16). Telomerase activity was detected in 6 
effusions from patients without evidence of cancer, and in 5 of them a large number of 
inflammatory cells was observed. However, the presence of inflammatory cells 
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(mainly lymphocytes) in om series, did not correlate with a positive TRAP assay. In 
12 specimens with a large number of inflammatory cells and no or only partly 
degraded rRNA no telomerase activity was detected. Thus, presence of large amount 
of lymphocytes does not lead by itself to a teiomerase positive assay. Among the 6 
patients with no evidence of cancer and effusion positive for telomerase activity, two 
of them had a rib fracture. Telomerase activity observed in these pleural effusions was 
likely due to presence of some bone marro'.v celis, presumably hematopoietic stem 
cells (25,26), and not to cancer cells. Although the other 4 patients showed no 
evidence of cancer, we cannot exclude the possibility that an occult malignant tUIllor 
was present. Probably a long follow-up will be necessary to classify these cases as 
either accurate malignant effusions or true false-positive telomerase results. Recently, 
lelomerase activity has been detected in the pancreatic juice of a patient 19 months 
before that a pancreatic cancer was diagnosed (27). In our series, two of the patients 
without evidence of malignant tumor had either a lupus erythematous or a 
Bronchiolitis Obliterans Organizing Pneumonia (BOOP), and some occult cancers 
have been shown to be associated with these diseases (28,29). Similar observation was 
done by other groups in some patients with tuberculosis (30,31), in tlus situation the 
appearance of a telomerase-positive pleural effusion could be due 10 undiagnosed 
concomitant cancer (32,33). Nevcrtheless, the occurrence of false-positive telomerase 
results due 10 cross-contamination between malignant and benign effusions also has to 
be considered. This is generally a main problcm when peR reactions have to be 
perfonned. We noticed that these 6 effusions were never in contact with an other 
telomerase positive case at the time of sample collcction and preparation before 
freezing. However, this observation is not sufficient to exclude definitively any 
contamination with other malignant cases. 
In some malignant effusions identified by cytologic examination, the TRAP 
assay failed to detect telomerase activity. One possible explanation may be that the 
cancer cells present in these effbsions had no telomerase activity. To explain the 
absence of telomerase activity in some tumors the existence of an alternative 
telomerase-independenl mechanism for cell immortality via telomere lengthening has 
been suggested (34,35). An other explanation could be due to the nature of the method 
used for measuring telomerase activity. Telomerase is a ribollucleoprotein enzyme that 
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uses its RNA as a template for the synthesis of TTAGGG repeats at the ends of the 
chromosomes. Thus, the feasibility of detecting lelomerase activity by the sensitive 
TRAP assay is dependent of the quality of RNA and protein cell components. In a 
previous work, we observed that telomerase activity is not always detectable in cells 
with strongly degraded RNA (23). This could explain why telomerase activity was not 
observed in some malignant e'ffusions. In our series, we observed that among the 8 
malignant fluids were telomerase activity was not detected, 6 of them had highly 
degraded RNA. FurthemlOre, absence of telomerase activity was more significantly 
(p=O.002) observed in fluids with highly degraded rRNA (8/38 cases, 21 %) than with 
relatively well preserved cells (28/53, 53%). Our results clearly indicatc that for a valid 
TRAP assay, the control ofrRNA quality is cssential in order to reduce the number of 
false-negative results. 
In conclusioll, our results suggest that, provided that the cell sample is 
sufficiently well preserved to allow for undegraded rRNA, telomerase activity could 
be a very sensitive marker for the presence of malignant cells in effusions. In this 
study, tclomerase activity was measured 011 routine sampling effusions, and thus this 
potential marker of malignancy could be lIscd without any change of the standard 
cytological protocols. Nevertheless, before the telomerase assay becomes a useful 
adjunct in routine cytologic examination, two main questions have to be clearly 
settled. For patients with telomerase positive effusions with presumably no preexisting 
cancer, additional studies with a long-follow-up and an in situ hybridization analysis, 
probably coupled with an immunocytochemistry, will be needed to determine whether 
malignant cells are really present in these effusions. In routine diagnosis, due to the 
cost of this assay, it is not conceivable 10 test the presence oftelomerase activity for all 
cytological benign effusions. Thus, a subgroup of them, with a relatively high 
percentage of tel om erase positivity, has to be detennined by a large scale prospective 
study. When these conditions will be achieved, the usc of telomerase in combination 
with cytology will be more reliable in the diagnosis of malignant cells in effusions. 
Acknowledgments: The authors thank Isabelle Roulin for excellent technical 
assistance. 
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CHAPTER VII 
Concluding remarks and sUlllluary 
102 
7.1 Concluding remarks 
Telomerase activity has been detected in almost all human cancer cell lines and in 
a majority of human cancers. Nevertheless, in about 10-15% of the reported human 
cancers telomerase activity was not detected (Kim et ai, 1994). Several interpretations 
should be considered for these tclomerase-negative tumour tissues. Firstly, evidence 
has been obtained that altemative mechanism(s) for lengthening of telomeres (ALT) 
might be involved in cellular immortalization, even though this remains elusive as yet 
(Reddel et aI, 1997; Bryan et ai, 1997). Secondly, assaying telomerase activity is 
subject to many pitfalls, including inadequate handing of samples, sampling artefacts 
and polymerase inhibitors. The positive intemal control included in the TRAP assay 
covers the problem of Taq polymerase inhibitors. However, a tissue quality control 
has never been proposed to date. We detected, in a series of 50 colorectal carcinomas, 
telomerase activity in all of25 cases with only partially degraded or intact RNA and in 
only 68% (17/25) cases with strongly or completely degraded RNA. This result 
demonstrates that in assaying telomerase activity tissue quality is of vital importance 
for reliable detection (Yan et ai, 1998). Human cancers are heterogeneous in many 
ways, including in the pattem of genetic alterations (Saraga et ai, 1997). In eorrelating 
histology with molecular parameters this should be taken into account in the 
experimental design. In a study of 30 colorectal adenomas, we observed close 
correlation between dysplasia grade and telomerase activity as detemlined on 
consecutive sections, which was lost when the grade established by routine 
pathological analysis was used. Clearly, proper controls and careful experimental 
designs are very important for getting more reliable results using TRAP assay. But, as 
pointed out by Meeker, lllallY published studies have not made careful use of such 
control (Meeker and Coffey, 1997). In our studies, both tissue quality control and 
histological controls were included in all experiments. 
As tclomerase seems to be activated in some preinvasive neoplastic lesions, 
assaying telomerase activity might be used as an early diagnostic tool. At which 
moment in the multistep pathogenesis telomerase activated remains to be clarified for 
most types of cancer. The colorectal adenoma-carcinoma sequence is one of the best 
characterised models for multistep tUlllorigenesis. The gradual progression from 
adenoma to carcinoma allows detailed analysis of the morphological and molecular 
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stage at which telomerase is activated. Telomemse is activated in almost all colorectal 
carcinomas. Its presence in adenomas remained, however, somewhat controversial and 
no infonnation was available in the relation between telomerase activity and grade of 
dysplasia in colorectal adenomas. We analysed telomerase activity, and in parallel 
with hTR RNA and hTERT mRNA subsequently in 25 colorectal carcinomas, 30 
colorectal adenomas and 15 samples ofnomlal colon mucosa. We found, strictly under 
controlled conditions, that all carcinomas and adenomas with high grade dysplasia, but 
only 20% of low grade dysplastic adenomas, show telomerase activity. These results 
indicate that telomerase is activated when adenomas progress from low grade 
dysplasia to high grade. This would place telomerase activation before p53 mutation 
but after K~ras mutation in Vogelstein's model of the molecular genetic pathway of 
colorectal carcinogenesis (Figure I). 
APC K~ras Telomerase p53 Olher 3clh'ation Changes? 
60-80% 35-45% 100% 40-fiO% \ 
--
Figure 1. Genetic pathway of coloreclal carcinogenesis. TIlis model proposed by Fearon and 
Vogelstein is based on the concept of an adenoma-carcinoma sequence. All the molecular genetic 
alterations shown in this model rarely occur together in :In individual. According to our results, 
telomerase activation will occur with a very high frequency between low grade to high grade dysplasia 
in adenomas. ACF: aberrant crypt foci. 
hTERT and hTR have been identified as the major components of the enzyme 
in a reconstitution experiment (Weinrich et ai, 1997). The expression of hTERT 
mRNA seems to be closely correlated with telomerase activity in cell lines and in 
human tissues, whereas hTR RNA as demonstrated by RT~PCR analysis is 
ubiquitously present in almost any tissue, irrespective of telomerase activity 
(Ramakrislman et aI, 1998; Takakura et aI, 1998; Kyo et ai, 1999), Consistent with 
other studies, we found that the expression ofhTERT mRNA perfectly correlated with 
telomerase activation in our group of colorectal carcinomas. As no intron sequences 
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exist in the hTR gene, after the reverse transcription step, the sequence of hTR eDNA 
will be identical to that of genomic hTR DNA. To detennine whether the ubiquitous 
expression of hTR might be due to a low level of transcription in various tissues or, 
aitematively, to amplification of genomic hTR DNA, extensive DNase I digestion 
before cDNA synthesis was perfonned in our study. After DNase digestion, hTR RNA 
was detected by RT-PCR mainly in telomerase-positive cases. Thus, when DNase 
digestion is omitted, the apparent broad expression of hTR RNA is probablY due to 
the amplification of contaminating genomic hTR DNA and not to hTR expression. Our 
results indicate that telomerase RNA component (hTR) is not as widely expressed as 
previously thought. 
Telomerase was found to be activated or upregulated in a majority of epithelial 
cancers and has been rapidly accepted as a potentially useful diagnostic and prognostic 
indicator in carcinoma and also more recently in gliomas. Little was known about 
teiomerase activity and its potential diagnostic and prognostic use in soft tissue 
lesions. We examined a series of benign and malignant soft tissue lesions for 
telomerase activity, hTERT mRNA expression and r-,'Iib-l labelling index. Telomerase 
activity was undetectable in benign soft tissue lesions and in low-grade soft tissue 
sarcomas, but detectable in 43% of the intennediate- and high-grade soft tissue 
sarcomas. A strong correlation bctween hTERT mRNA expression and telomerase 
activity was observcd, but there was no correlation between Mib-l labelling index and 
telomerase activity. The absence oftelomerase activity was not due to the presence of 
telomerase inhibitors. An altemative mechanism for lengthening of telomeres (ALT) 
might be involved in the development and lor maintenance of some soft tissue 
sarcomas. Such a mechanism might be operative in some sarcomas and sarcoma cell 
lines, but it is unlikely to be universal. Recent data has shown that homogeneous 
distribution pattems of TRF (temlinal restriction fragments) occurred in malignant 
schwanl10mas and malignant fibrous histocytoma. The fanner have shortened telomere 
length and the latter have nomlal telomere length. A very heterogeneous distribution 
pattem ofTRF was perceived in liposarcomas (Schneider-Stock ct aI, 1998 and 1999). 
Therefore, additional studies in soft tissue sarcomas are needed to clarify the 
relationship between telomerase activity and telomere length. Our results indicate that 
telomerase activity is restricted to a subset of intennediate- and high-grade sarcomas 
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and, as yet, cannot be lIsed as a diagnostic or prognostic tool. Sarcomas might provide 
an interesting model to study altemative mechanisms for lengthening ofte!omeres. 
Several studies have shown that telomerasc activity can be detected in almost 
any type of clinical specimen, including exfoliated cells and fine needle aspirates. 
Although cytological examination is presently considered to be the most specific 
method for diagnosis of malignant effusions, this approach has its limitations 
(Jolmston et ai, 1985). The detection of tcJomerase activity might be a helpful tool to 
difierentiate benign from malignant effusions. In our study, 42% (38/91) of the 
effusions with a strong clinical sllspicion of malignancy were positive by combining 
cytology and telomerase detection, whereas only 30% (27/91) of samples were 
positive by cytology only. Therefore, telomerase activity could be a very sensitive 
marker for the presence of malignant cells in erfusions. Additional studies with long-
follow-up and in situ analysis by in situ hybridization and immunocytochemistry are 
needed to detennine whether malignant cells are really present in these effusions. 
Potentially, telomerase activation in combination with cytology might be more reliable 
than cytology only in Ihe diagnosis of malignant cells in effusions. 
106 
References 
l. Bryan TM, Englezou A, Dalla-Pozza L, Dunham MA and Reddel RR. (1997) 
Evidence for an altemativc mechanism for maintaining telomere length in human 
tumors and tumor-derived cell lines. Nat Med, 3: 1271-4. 
2. Johnston ''''V. (1985) The malignant pleural effusion. A review ofcytopathologic 
diagnoses of584 specimens from 472 consecutive patients. Cancer, 56:905-909. 
3. Kyo S, kallaya T, Takakura M, Tanaka M, Yamashita A, Inoue H, and Inoue M. 
(1999) Expression of human telomerase subunits in ovarain malignant borderline 
and benign tumors. Inti J Cancer, 80:804-809. 
4. Meeker AK and Coffey DS. (1997) TeloJllerase: a promising marker of biological 
immortality of genn, stem, and cancer cells. A revicw. Biochemistry, 62: 1323-
133l. 
5. Ramakrishnan S, Eppenbergcr V, Mueller H, Shillkai Y and Narayanan R(1998) 
Expression profile of the putative catalytic subunit of the telomerasc gene. Cancer 
Res, 58:622-625. 
6. Reddel RR, Bryan TM and Mumane JP. (1997) Immortalized cells with no 
detectable telomerasc activity. A rcview. Biochemistry (Moscow), 62: 1254-62. 
7. Rcddel RR, Bryan TM and Mumane JP, (1997) Immortalized cells with no 
detectable telomerase activity. A review. Biochemistry (Moscow), 62:1254-62. 
8, Saraga E, Bautista D, Dorta G, Chaubert P, Martin p, Sordat B, Protiva P, Blum A, 
Bosman F and Benhattar 1. (1997) Genetic heterogeneity in sporadic colorectal 
adenomas, J Pathol, 181:281-6. 
9. Schncider-Stock R, EppIen C, Radig K, Oda Y, Dralle H, Hoang-Vu C, Epplen JT 
and Roessner A. On telomere shortening in soft-tissue tumors. (1998) J Cancer Res 
& Clin Oncol, 124:165-71. 
10.Schneider-Stock R, Epplen JT, Walter H, Radig K, Rys J, Epplen C, Hoang-Vu C, 
Niezabitowski A and Roessner A,(l999) TeIomeric lengths and telomerase activity 
in liposarcomas. Molecular Carcinogenesis, 24: 144-51. 
11.Tahara H, Kuniyasu H, Yokozaki H, Yasui W, Ide T and Tahara E. (1995) 
telomerasc activity in preneoplastic and neoplastic gastric and colorectal lesions. 
Clin Cancer res, 1:1245-1251. 
12.Yau P, Bosman FT and Benhattar J. (1998) Tissue quality is an important 
detemlinant oftelomerase activity as measured by the TRAP assay. Biotechniqucs, 
25: 660-662. 
107 
7.2 Summary 
The telomere-telomerase hypothesis of cell senescence and inmlOrtalization has 
rapidly become a focus of intensive research in the field of carcinogenesis. In our 
studies, we investigated tclomerase activity in colorectal carcinogenesis, in soft tissue 
lesions and in cytological specimens. Chapter 2 describes the importance of tissue 
quality control in TRAP assay. Our results indicated that if cellular RNA is partially 
degraded or intact, more reliable results will be obtained. Contrary, if cellular RNA is 
strongly degraded, te!omerase activity is not always observed. To avoid false-negative 
results due to sampling error, the control of RNA quality is an essential step in 
assaying telomerase activity. In chapter 3, with tissue quality control and histological 
control, we found that tclomerase is activated in adenomas during progression from 
low grade to high grade dysplasia. We suppose that telomerase positive low grade 
dysplastic adenomas may have a higher risk to progress towards high grade dysplastic 
adenoma and carcinoma than do those without telomerase activity. FurthemlOre, we 
studied the expression of hTR RNA and hTERT mRNA in colorectal tissues in 
chapter 4. A significant correlation was observed between telomerase activation and 
the expression ofhTERT mRNA and hTR RNA, detenllined by RT-PCR. As no intron 
sequences exist in the hTR gene, after the reverse transcription step the sequence of 
hTR cDNA will be identical to that of genomic hTR DNA. To avoid this problem, 
extensive DNase digestion was perfonned before hTR cDNA synthesis in our RT~ 
peR. In chapter S, we examined teiomerase activity in a series of benign and 
malignant soft tissue lesions and evaluated the relationship between telomerase 
activation and the expression of hTERT mRNA as well as Mib~l labelling index. 
Telomerase activity was not observed in benign soft tissue lesions, in low~grade soft 
tissue sarcomas (STS), neither in about 50% of intennediate- and high-grade STS. A 
strong correlation between hTERT mRNA expression and telomerase activity was 
observed, but there was no relationship between Mib-l labelling index and telomerase 
activity. Telomerase activity, as yet, can not be used as a diagnostic or prognostic tool 
in soft tissue sarcomas. Sarcomas might provide an interesting model to study the 
altemative mechanisms for lengthening of telomeres. In experiments of chapter 6, 
TRAP assay and cytological examinations were perfonned in 91 pleural, peritoneal 
and pericardial effusions. 42% (38/91) of tile effusions with a strong clinical suspicion 
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of malignancy were positive by combining cytology and telomerase detection, whereas 
only 30% (27/91) of samples were positive by cytology only. Provided that sample of 
adequte RNA quality are used, telomerase activity could be come a helpful parameter 
for detecting malignant cells in effusion samples. 
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SAMENVA TIING 
In korlc lijd heeft de lelomeer-telomerase hypothese, ler veklaring van cellulaire 
veroudering en immortalisatie, bclangrijke aandacht wcten Ie Irekken in he! kanker 
onder LOck. In dit proefschrift wordt onderzoek beschreven flaar telomerase activiteit in de 
colorectale carcinogenesc, in weke delen tumorcn en in cytologisch materiaal. 
In hoofdstuk 2 wordt het belang van controle procedures voor de weefselkwalitei! bij 
de TRAP-assay besproken. Onze resultalen geven aan d<lt betrouwbare uitkomsten met deze 
test aileen dan vcrkregen h.'lillnen wotrden als hel cellulaire RNA intact of hooguit len dele 
gedesinlegreerd is. Ais het RNA sterke desintegratie verloont IlCeft een negatief testresultaat 
geen betckenis. Om fout-negatieve testuitslagen Ie voorkomen is het onderzoek naar de 
integriteil van het RNA derhalvc onmisba<lr. 
In hoofdsluk 3 wordt onderzoek naar tc1omerase-activiteit in coloreclale lumorcn 
beschrcven. Weefselbvaliteit werd bewaakt yolgens de hierhoven beschrcven procedure en 
de monsters yoor de TRAP-assay werden histologisch gecontroleerd op de aanwezigheid en 
klassificalic van tumor. Het bleek dat teiomerasc wordl geactiveerd bij de overgang van 
adenonlen met laaggradige naar hooggradigc dyslasie. We veronderstellen dal telomerase-
positieve laaggradige adenomen een !,'Tolere kans hebben zich te ontwikkclcn tot hooggradig 
adenoom of carcinoom dan telomcrase negatieve. 
Verder onderzochten we de expressie van hTR RNA en hTERT mRNA in colorectaal 
carcinoom. Dil onderzoek wordt beschreven in hoofdstuk 4. We vonden met behulp van RT-
peR ecn significante correlatie lussen tc10merase aeti\'utie en dc expressie van hTERT 
mRNA en hTR RNA. Omdat er in het hTR gcn geen intronsekwenties voorkomen is het 
cDNA dat verkregen wordl na 'reverse' transcriptie van hTR RNA identiek aan de 
genomische hTR DNA sekwenlie. Om co-amplificatie van genomisch DNA te voorkomen 
werd het monster behandeld met DNAse yooraf"£aand a<ln de hTR eDNA synthese. 
In hoofdstuk 5 wordt onderzoek beschreven naar teiomerase activiteit in eell serie 
goed- en kwaadaardige weke delen tumoren. We evaluccrden de correlatie tusscn te10merase 
activiteit en de expressie van hTERT nlRNA en de jI,·IIB-l labeling index. Telomerase-
acliviteit werd niet gevondcn in goedaardigc lcsies, evenmin in l<laggradige weke delen 
sarcomen en in niet meer dan 50% van de intemlediaire en haoggradige weke delen 
sarcomen. Er bleek een sterkc correlatie te bestaan tussen lelomerasc aetiviteit en hTERT 
mRNA expressie maar niet met de I\HB-l labeling index. Telomerase aclivutie heeft derhalve 
bij de klassifikatic van weke delen tumorcn geen praktischc bctekenis. Sarcomen zijn weI een 
interessanl substraat voar onderLOck naar altemalic\'c mechanismen van tclomeerverlenging. 
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In hoofdstuk 6 wordt ondcrzoek bcschreven naar tclomerase activiteit in cytologisch 
materiaal mct behulp van de TRAP assay. Van 91 monsters van pleura-, pericard- en 
ascitesvocht met hoge klinische \'crdcnking op maligniteit was 42% (38/91) positief in de 
TRAP assay enlof bij cytologisch onder-LOck. Cytologisch onderzoek aileen was positicf in 
slechts 30% (27/91) van de monsters. Voorop gesteld dat de RNA integriteit van het monster 
voldoende is, kan de bepaling van telomerase in cell cytologisch monster wcllicht een 
bijdrage levercn aan de detectie vall ttllIlorcellcn in lichaams\'ochten. 
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